Antidepressants for treating depression in dementia by Dudas, Robert et al.
Cochrane Database of Systematic Reviews
Antidepressants for treating depression in dementia (Review)
Dudas R, Malouf R, McCleery J, Dening T
Dudas R, Malouf R, McCleery J, Dening T.
Antidepressants for treating depression in dementia.
Cochrane Database of Systematic Reviews 2018, Issue 8. Art. No.: CD003944.
DOI: 10.1002/14651858.CD003944.pub2.
www.cochranelibrary.com
Antidepressants for treating depression in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
T A B L E O F C O N T E N T S
1HEADER . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
1ABSTRACT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
2PLAIN LANGUAGE SUMMARY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
4SUMMARY OF FINDINGS FOR THE MAIN COMPARISON . . . . . . . . . . . . . . . . . . .
7BACKGROUND . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8OBJECTIVES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
8METHODS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10RESULTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Figure 1. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Figure 2. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Figure 3. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 15
Figure 4. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 17
Figure 5. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 18
Figure 6. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 7. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Figure 8. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 21
22DISCUSSION . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24AUTHORS’ CONCLUSIONS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24ACKNOWLEDGEMENTS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
24REFERENCES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
30CHARACTERISTICS OF STUDIES . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
59DATA AND ANALYSES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
60ADDITIONAL TABLES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
64WHAT’S NEW . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
64HISTORY . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
65CONTRIBUTIONS OF AUTHORS . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
66DECLARATIONS OF INTEREST . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
66SOURCES OF SUPPORT . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
67DIFFERENCES BETWEEN PROTOCOL AND REVIEW . . . . . . . . . . . . . . . . . . . . .
67NOTES . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
67INDEX TERMS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
iAntidepressants for treating depression in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
[Intervention Review]
Antidepressants for treating depression in dementia
Robert Dudas1 ,2, Reem Malouf3, Jenny McCleery4, Tom Dening5
1Department of Psychiatry, University of Cambridge, Cambridge, UK. 2Older People’s Mental Health Service, Cambridge and Peter-
borough NHS Foundation Trust, Cambridge, UK. 3National Perinatal Epidemiology Unit (NPEU), University of Oxford, Oxford,
UK. 4Oxford Health NHS Foundation Trust, Banbury, UK. 5Division of Psychiatry & Applied Psychology, The University of Not-
tingham, Nottingham, UK
Contact address: Robert Dudas, Department of Psychiatry, University of Cambridge, Addenbrooke’s Hospital, Hills Road, Cambridge,
CQ2 2QQ, UK. rbd21@cam.ac.uk.
Editorial group: Cochrane Dementia and Cognitive Improvement Group.
Publication status and date: New search for studies and content updated (conclusions changed), published in Issue 8, 2018.
Citation: Dudas R, Malouf R, McCleery J, Dening T. Antidepressants for treating depression in dementia. Cochrane Database of
Systematic Reviews 2018, Issue 8. Art. No.: CD003944. DOI: 10.1002/14651858.CD003944.pub2.
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
A B S T R A C T
Background
The use of antidepressants in dementia accompanied by depressive symptoms is widespread, but their clinical efficacy is uncertain. This
review updates an earlier version, first published in 2002.
Objectives
To determine the efficacy and safety of any type of antidepressant for patients who have been diagnosed as having dementia of any type
and depression as defined by recognised criteria.
Search methods
We searched ALOIS, the Cochrane Dementia and Cognitive Improvement Group’s Specialised Register, on 16 August 2017. ALOIS
contains information on trials retrieved from databases and from a number of trial registers and grey literature sources.
Selection criteria
We included all relevant double-blind, randomised trials comparing any antidepressant drug with placebo, for patients diagnosed as
having dementia and depression.
Data collection and analysis
Two review authors selected studies for inclusion and extracted data independently. We assessed risk of bias in the included studies
using the Cochrane ’Risk of bias’ tool. Where clinically appropriate, we pooled data for treatment periods up to three months and from
three to nine months. We used GRADE methods to assess the overall quality of the evidence.
Main results
We included ten studies with a total of 1592 patients. Eight included studies reported sufficiently detailed results to enter into analyses
related to antidepressant efficacy. We split one study which included two different antidepressants and therefore had nine groups of
patients treated with antidepressants compared with nine groups receiving placebo treatment. Information needed to make ’Risk of
bias’ judgements was often missing.
We found high-quality evidence of little or no difference in scores on depression symptom rating scales between the antidepressant and
placebo treated groups after 6 to 13 weeks (standardised mean difference (SMD) -0.10, 95% confidence interval (CI) -0.26 to 0.06;
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614 participants; 8 studies). There was probably also little or no difference between groups after six to nine months (mean difference
(MD) 0.59 point, 95% CI -1.12 to 2.3, 357 participants; 2 studies; moderate-quality evidence). The evidence on response rates at
12 weeks was of low quality, and imprecision in the result meant we were uncertain of any effect of antidepressants (antidepressant:
49.1%, placebo: 37.7%; odds ratio (OR) 1.71, 95% CI 0.80 to 3.67; 116 participants; 3 studies). However, the remission rate was
probably higher in the antidepressant group than the placebo group (antidepressant: 40%, placebo: 21.7%; OR 2.57, 95% CI 1.44 to
4.59; 240 participants; 4 studies; moderate-quality evidence). The largest of these studies continued for another 12 weeks, but because
of imprecision of the result we could not be sure of any effect of antidepressants on remission rates after 24 weeks. There was evidence
of no effect of antidepressants on performance of activities of daily living at weeks 6 to 13 (SMD -0.05, 95% CI -0.36 to 0.25; 173
participants; 4 studies; high-quality evidence) and probably also little or no effect on cognition (MD 0.33 point on the Mini-Mental
State Examination, 95% CI -1.31 to 1.96; 194 participants; 6 studies; moderate-quality evidence).
Participants on antidepressants were probably more likely to drop out of treatment than those on placebo over 6 to 13 weeks (OR 1.51,
95% CI 1.07 to 2.14; 836 participants; 9 studies). The meta-analysis of the number of participants suffering at least one adverse event
showed a significant difference in favour of placebo (antidepressant: 49.2%, placebo: 38.4%; OR 1.55, 95% CI 1.21 to 1.98, 1073
participants; 3 studies), as did the analyses for participants suffering one event of dry mouth (antidepressant: 19.6%, placebo: 13.3%;
OR 1.80, 95% CI 1.23 to 2.63, 1044 participants; 5 studies), and one event of dizziness (antidepressant: 19.2%, placebo: 12.5%; OR
2.00, 95% CI 1.34 to 2.98, 1044 participants; 5 studies). Heterogeneity in the way adverse events were reported in studies presented a
major difficulty for meta-analysis, but there was some evidence that antidepressant treatment causes more adverse effects than placebo
treatment does.
Authors’ conclusions
The available evidence is of variable quality and does not provide strong support for the efficacy of antidepressants for treating depression
in dementia, especially beyond 12weeks. On the onlymeasure of efficacy for whichwe had high-quality evidence (depression rating scale
scores), antidepressants showed little or no effect. The evidence on remission rates favoured antidepressants but was of moderate quality,
so future research may find a different result. There was insufficient evidence to draw conclusions about individual antidepressant drugs
or about subtypes of dementia or depression. There is some evidence that antidepressant treatment may cause adverse events.
P L A I N L A N G U A G E S U M M A R Y
Antidepressants for treating depression in dementia
Review question
We reviewed the evidence about the effect of antidepressants on depression in people with dementia.
Background
Depression can be hard to recognise in people with dementia, but there is evidence that it is common and associated with increased
disability, poorer quality of life, and shorter life expectancy.Many peoplewith dementia are prescribed antidepressants to treat depression,
but there is uncertainty about how effective this is.
This review updates an earlier version, first published in 2002.
Search date
We searched up to August 2017 for relevant studies.
Study characteristics
We found ten studies with 1592 people to include in the review. On average, the studies lasted only 12 weeks, although one study ran
for nine months. Each of them used a set of formal criteria to diagnose both depression and dementia and compared an antidepressant
against a dummy pill (placebo).
The older studies used more old-fashioned antidepressants (imipramine, clomipramine, and moclobemide) and the newer studies
used more modern ones, such as venlafaxine, mirtazapine and so-called SSRI antidepressants (sertraline, fluoxetine, citalopram and
escitalopram).
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The people taking part in the studies had an average age of 75 and they had mild or moderate dementia. With the exception of two
studies, they were being treated as outpatients.
Key results
We found that there was little or no difference in scores on depression rating scales between people treated with antidepressants and
those treated with placebo for 12 weeks. The evidence to support this finding was of high quality, which suggests that further research
is unlikely to find a different result. There was probably also little or no difference after six to nine months of treatment.
Another way to assess the effect of antidepressants is to count the number of people in the antidepressant and placebo groups who
show significant clinical improvement (response) or who recover from depression (remission). There was low-quality evidence on the
number of people showing a significant clinical improvement and the result was imprecise so we were unable to be sure of any effect
on this measure. People taking an antidepressant were probably more likely to recover from depression than were those taking placebo
(antidepressant: 40%, placebo: 21.7%). There was moderate-quality evidence for this finding, so it is possible that further research
could find a different result.
We found that antidepressants did not affect the ability to manage daily activities and probably had little or no effect on a test of
cognitive function (which includes attention, memory, and language).
People taking an antidepressant were probably more likely to drop out of treatment and to have at least one unwanted side effect.
Quality of the evidence
The quality of the evidence varied, mainly due to poorly conducted studies and problems with the relevance of the outcome measures
used. This should be taken into consideration when interpreting the different results on depression rating scales and recovery rates, as
evidence was of a higher quality for the former than for the latter.
Another major problem is that side effects are very rarely well-reported in studies.
Therefore, further research will still be useful to reach conclusions that are more reliable and can better help doctors and patients to
know what works for whom.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Antidepressant treatment compared with placebo for depression in dementia
Patient or population: pat ients with depression and dementia
Settings: outpat ient (except Roth 1996, which was mixed in- and outpat ients)
Intervention: ant idepressant treatment
Comparison: placebo treatment
Outcomes Illustrative comparative risks* (95% CI) Relative effect
(95% CI)
No of Participants
(studies)
Quality of the evidence
(GRADE)
Comments
Assumed risk Corresponding risk
Placebo Antidepressant
Depression endpoint
mean scores at 6 to 13
weeks
The standardised de-
pression rat ings scale
endpoint mean score
in the ant idepressant
group was 0.10 points
lower (0.26 lower to 0.
06 higher)
614
(8)
⊕⊕⊕⊕
high
No evidence of an ef -
fect of ant idepressants
on depression in de-
mentia
Number of responders
(ITT) at 6 to 12 weeks
377 per 1000 509 per 1000
(326 to 690)
OR 1.71 (0.80 to 3.67) 116
(3 studies)
⊕⊕©©
low1
No evidence of an ef -
fect of ant idepressants
regarding response to
treatment for depres-
sion in dementia
Number of patients
with remission (ITT) at
6 to 12 weeks
217 per 1000 415 per 1000
(285 to 559)
OR 2.57 [1.44, 4.59] 240
(4)
⊕⊕⊕©
moderate2
Evidence of a posit ive
ef fect of ant idepres-
sants on remission of
depression in dementia
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Cognitive function
endpoint mean scores
at 6 to 12 weeks
The MMSE endpoint
mean score in the an-
t idepressant group was
0.33 points higher [1.
31 lower to 1.96 higher]
(194)
(5)
⊕⊕⊕©
moderate3
No evidence of an ef -
fect of ant idepressants
on cognit ive funct ion
in pat ients with depres-
sion and dementia
Activities of daily liv-
ing, endpoint values at
6 to 13 weeks
The standardised mean
dif ference in ADL end-
point mean scores
in the ant idepressant
group was 0.05 points
lower [0.36 lower to 0.
25 higher]
173
(4)
⊕⊕⊕⊕
high
No evidence of an ef -
fect of ant idepressants
on ADLs in pat ients with
depression and demen-
t ia
Number of dropouts at
6 to 13 weeks
179 per 1000 248 per 1000
(189 to 318)
OR 1.51
(1.07 to 2.14)
836
(9)
⊕⊕⊕©
moderate4
Evidence of a nega-
t ive ef fect of ant ide-
pressants on staying in
treatment in pat ients
with depression in de-
mentia
Number of patients ex-
periencing at least one
adverse event
384 per 1000 492 per 1000
(430 to 553)
OR 1.55
(1.21 to 1.98)
1073
(5)
⊕⊕⊕©
moderate5
Evidence of a negat ive
ef fect of ant idepres-
sants related to side ef -
fects in pat ients with
depression and demen-
t ia
* The basis for the assumed risk (e.g. the median control group risk across studies) is provided in footnotes. The corresponding risk (and its 95% conf idence interval) is
based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its 95%CI).
CI: Conf idence interval; OR: Risk Ratio; ITT: intent ion-to-treat; MMSE: Mini-Mental State Examinat ion
A SMD of 0.2 is of ten considered to represent a small ef fect size, 0.5 a moderate ef fect size and 0.8 a large ef fect size
GRADE Working Group grades of evidence
High quality: we are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate quality: we are moderately conf ident in the ef fect est imate: the true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
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Low quality: our conf idence in the ef fect est imate is lim ited: the true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low quality: we have very lit t le conf idence in the ef fect est imate: the true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
1The quality of the evidence was downgraded due to indirectness (the def init ions of “response” were dif ferent in the studies
and some could be considered surrogate measures, e.g. “best clinical judgement”) and imprecision (comparison was
underpowered due to low number of total number of part icipants).
2The quality of the evidence was downgraded due to indirectness (the def init ions of “remission” were dif ferent in the studies
and some could be considered surrogate measures, e.g. “best clinical judgement”).
3The quality of the evidence was downgraded due to imprecision (relat ively low number of part icipants and wide conf idence
intervals).
4 The quality of the evidence was downgraded due to imprecision (the analysis is underpowered; also, the 95% CI around the
pooled or best est imate of ef fect include both lit t le ef fect and appreciable harm).
5The quality of evidence was downgraded due to select ive report ing.
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B A C K G R O U N D
Description of the condition
People with dementia are commonly afflicted with depression
(Bennet 2014; Leyhe 2017) and depression is associated with in-
creased disability, impaired quality of life, and higher mortality
(Black 2012; Diniz 2013; Vaughan 2015).
However, both depression and dementia are concepts with neb-
ulous boundaries. Depressive illness has been conceptualised in
dimensional and categorical terms with no consensus about its
fundamental nature. When conceptualised dimensionally, depres-
sion’s various presentations are explained by their position on a
continuum of increasing severity. When conceptualised categori-
cally, depressive illness is sub-grouped into discrete entities such as
melancholic or non-melancholic depression and anxious depres-
sion (Parker 2000). Dementia is a syndrome that may arise from a
variety of underlying pathologies, the most common of which are
Alzheimer’s disease, vascular dementia, and dementia with Lewy
bodies.
Given the complex nature of both depression and dementia, un-
derstanding the relationship between the two is difficult. Depres-
sive illness in older people can present as ’pseudodementia’ and be
difficult to distinguish from a dementing illness (Raskind 1998).
On the other hand, depression is often associated with deteriora-
tion in cognitive functioning which is sometimes not completely
reversible with treatment (Abas 1990). Moreover, in older peo-
ple a history of depression in later life may be associated with
an increased risk of subsequently developing a dementing illness
(Naismith 2010; Byers 2011; Barnes 2012; Heser 2013; Diniz
2013). Both disorders are common in older people and may there-
fore be expected to occur together solely by chance.
Because of these complexities, diagnosing depression in patients
with dementia can be difficult. Denial and cognitive impairment
may compromise self-report of depressive symptoms by people
with dementia. As the dementing illness progresses, the presenta-
tion of depression may alter, with non-verbal manifestations (e.g.
demanding behaviour, clinging) being more apparent than cogni-
tive features (Vida 1994). Moreover, neurovegetative (autonomic)
symptoms such as poor concentration and anhedonia (reduction
in or complete lack of ability to enjoy activities the person usu-
ally finds enjoyable) are features of both depression and dementia.
Not surprisingly, there is no consensus on how best to diagnose
depression in demented patients. Depression symptom scales may
overestimate, whereas structured diagnostic interviewsmay under-
estimate, the prevalence of depression in people with dementia.
Only one instrument - the Cornell Scale for Depression in De-
mentia (CSDD, Alexopoulos 1988) - has been specifically devel-
oped for use in a population with dementia. Given the complexity
of the issues impinging on accurate diagnosis, it is not surpris-
ing that estimates of the incidence and prevalence rates of depres-
sion in patients with dementia vary between 0% and 86%. Larger
studies using standardised criteria for major depressive disorder in
Alzheimer’s disease provide estimates of prevalence at 10% to 20%
(Loreck 1993).
Description of the intervention
Drugs licensed as antidepressants are a heterogeneous group. They
are commonly described as falling into a number of classeswith dif-
ferent mechanisms of action, although the various classes are gen-
erally reported to be of similar efficacy (Anderson 2000; Williams
2000). However, different drugs or classes of drugs may vary in
their efficacy or safety in the depression of dementia, or may be
preferentially effective in particular subtypes of dementia.
The oldest class of antidepressants is the tricyclic antidepres-
sants (TCAs), including drugs such as amitriptyline, imipramine,
clomipramine and nortriptyline. As a class, they are associatedwith
side effects that are potentially more problematic for older than for
younger patients. In particular, their anticholinergic properties are
associated with a negative impact on cognition (Settle Jr 1998).
Other problematic anticholinergic effects would include increased
intra-ocular pressure, urinary retention, dry mouth, and constipa-
tion. Due to their anti-adrenergic side effects, they can also cause
postural hypotension (Glassman 1981), and dizziness, thereby in-
creasing the risk of falls. A second class of antidepressants, the se-
lective serotonin reuptake inhibitors (SSRIs), is now more widely
used for older people. SSRIs include fluoxetine, paroxetine, sertra-
line, citalopram, and escitalopram. These drugs have a different
range of side effects, most notably nausea and vomiting, agitation,
anxiety, indigestion, diarrhoea or constipation, loss of appetite and
weight loss, dizziness, blurred vision, dry mouth, excessive sweat-
ing, insomnia or drowsiness, headaches, and sexual side effects.
However, they have less marked anticholinergic and anti-adren-
ergic properties and therefore may be less likely to cause confu-
sion or falls ( Avorn 1998). Other antidepressant drug classes in-
clude selective serotonergic and noradrenergic reuptake inhibitors
(SNRIs) such as venlafaxine and duloxetine, tetracyclic anti-de-
pressants such as trazodone and maprotiline, and the reversible
monoamine oxidase inhibitors (MAOIs), such as moclobemide.
Another often used example of the newer antidepressants is the
alpha2-antagonist mirtazapine.
Why it is important to do this review
Dementia with depression is a common and important clinical
problem. A recent Cochrane Review of psychological treatments
for depression in dementia found evidence for benefit, but it was
poor-quality, heterogeneous evidence (Orgeta 2014). The use of
antidepressants for patients with dementia accompanied by de-
pressive symptoms is widespread, but their clinical efficacy is un-
certain. This uncertainty is due in part to the difficulties of inter-
preting the results of clinical trials. Many of the individual trials
7Antidepressants for treating depression in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
of antidepressants have been too small to provide precise estimates
of the benefits that might realistically be expected. Combining the
information from all appropriate trials may provide a better esti-
mate of the likely effects of treatment.
O B J E C T I V E S
To determine the efficacy and safety of any type of antidepressant
for patients who have been diagnosed as having dementia of any
type and depression as defined by recognised criteria.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We considered all identified relevant double-blind, randomised,
placebo-controlled trials of longer than four weeks’ duration. Trials
in which the allocation to treatment or placebo was not random,
or in which treatment allocation was not concealed, were excluded
(Altman 1999).
Types of participants
Inclusion criteria
To ensure participants of included trials were comparable, sub-
jects were required to meet accepted diagnostic criteria. We in-
cluded trials involving participants with dementia as diagnosed by
accepted criteria such as DSM (APA 1987), NINCDS-ADRDA
(McKhann 1984) and ICD-10 (WHO 1992), with a coexisting
depressive illness as diagnosed by similarly accepted criteria. Par-
ticipants could be of either sex and of any age.
Exclusion criteria
Weexcluded studies of patientswith dementia suffering fromemo-
tional disorders or behavioural problems, but falling short of a
diagnosis of depression (as diagnosed by recognised criteria).
Types of interventions
Inclusion criteria
Any antidepressant medication listed in the British National For-
mulary number 73, 2017 (see Electronic searches for list of antide-
pressants) compared with placebo. There was no minimum dose
requirement for inclusion.
Exclusion criteria
We excluded trials of euphoriants (e.g. amphetamines), adjuvants
(e.g. lithium), combination treatments (e.g. ’Motipres’), studies
of other drug classes not generally regarded primarily as antide-
pressants (e.g. antipsychotics), and agomelatine, which is contra-
indicated in dementia.
Types of outcome measures
The outcomes of interest were as follows (Table 1 summarises the
outcome measures analysed in this paper).
Primary outcomes
Effect on depression (measured by rating scales, and by rates of
response or remission defined according to clear criteria).
Secondary outcomes
1. Effect on cognitive function (measured by validated
psychometric tests).
2. Effect on activities of daily living (measured by validated
rating scales).
3. Effect on quality of life (measured by validated rating
instruments).
4. Tolerability (measured by withdrawal from trial).
5. Safety (measured by the incidence of adverse effects).
Search methods for identification of studies
Electronic searches
We searched ALOIS ( www.medicine.ox.ac.uk/alois), the
Cochrane Dementia and Cognitive Improvement Group’s Spe-
cialized Register on 16 August 2017. The search was done on a
tag used in ALOIS for studies in which the following antidepres-
sant terms have been used: antidepressant, amitriptyline, lentizol,
tryptizol, triptafen, amoxapine, asendis, clomipramine, anafranil,
dothiepin, perothiaden, doxepin, sinequan, imipramine, tofranil,
lofepramine, gamanil, nortriptyline, allegron, protriptyline, con-
cordin, trimipramine, surmontil, maprotiline, ludiomil, mi-
anserin, mirtazapine, zispin, trazodone, molipaxin, viloxazine, vi-
valan, phenelzine, nardil, isocarboxazid, tranylcypromine, par-
nate, moclobemide, manerix, fluoxetine, prozac, citalopram,
cipramil, fluvoxamine, faverin, paroxetine, seroxat, sertraline, lus-
tral, nefazadone, dutonin, venlafaxine, efexor, flupenthixol, de-
pixol, fluanxol, reboxetine, edronax, tryptophan, optimax, esci-
talopram, cipralex, dosulepin, dothapex, prepadine, and vortiox-
etine.
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ALOIS is maintained by the Information Specialist for the
CochraneDementia and Cognitive ImprovementGroup and con-
tains studies in the areas of dementia prevention, dementia treat-
ment and cognitive enhancement in the healthy. The studies are
identified from:
1. monthly searches of a number of major healthcare
databases: MEDLINE, Embase, Cinahl, PsycINFO and Lilacs;
2. monthly searches of a number of trial registers: UMIN
(Japan’s Trial Register); ICTRP/the WHO portal (which covers
ClinicalTrials.gov; ISRCTN; the Chinese Clinical Trials Register;
the German Clinical Trials Register; the Iranian Registry of
Clinical Trials and the Netherlands National Trials Register, plus
others);
3. quarterly search of the Cochrane Library’s Central Register
of Controlled Trials (CENTRAL);
4. six-monthly searches of a number of grey literature sources:
ISI Web of Knowledge Conference Proceedings; Index to
Theses; Australasian Digital Theses.
To view a list of all sources searched for ALOIS, see About ALOIS
on the ALOIS website.
Details of the search strategies used for the retrieval of reports of
trials from the healthcare databases, CENTRAL and conference
proceedings can be viewed in the ‘methods used in reviews’ sec-
tion within the editorial information about the Dementia and
Cognitive Improvement Group.
Additional searches were performed in many of the sources listed
above to cover the timeframe from the last searches performed for
ALOIS to ensure that the search for the review was as up-to-date
and as comprehensive as possible. The search strategies used can
be seen in Appendix 1.
Searching other resources
We consulted a number of experts in old age psychiatry. We also
asked the medical information departments of major pharmaceu-
tical companies to search databases and their records for trials in-
volving their products. In addition, we searched reference lists of
retrieved studies and review articles.
Data collection and analysis
Selection of studies
A single review author (for the first edition: JB [see Contributions
of authors for full names], for the current revision: RD) discarded
irrelevant citations identified by searches, based on the title of the
publication and its abstract. If there was any suggestion that an
article could be relevant, it was retrieved for further assessment.
Two review authors (first edition: JB and JSB, current revision:
RD and TD) then independently selected the trials for inclusion
in the review from the culled citation list.
Data extraction and management
For the original review, data were independently extracted by two
review authors (JB, JSB) and cross-checked. Any discrepancies
were discussed and adjudicated by a third reviewer (TD). For the
current revision, data were extracted by the first author (RD). Data
were sought on every participant for each outcome measure. To
allow an intention-to-treat analysis, we sought data irrespective
of compliance, whether or not the participant was subsequently
deemed ineligible, or otherwise excluded from treatment or follow-
up.
If ordinal scale data appeared to be approximately normally dis-
tributed, or if the analysis that the investigators performed sug-
gested that parametric tests were appropriate, then we treated the
outcome measures as continuous data. Where the outcome mea-
sure was a continuous variable or ordinal variable (such as psycho-
metric test scores, clinical global impression scales, functional and
quality of life scales) we extracted summary statistics, including
means, standard deviations (SDs) and number in each treatment
group, for the final assessment score (corrected for baseline) and
the change in score from baseline (i.e. pre-randomisation or ran-
domisation) to the final assessment for each study. For dichoto-
mous outcomes, the statistics extracted from each study were the
numbers in each treatment group and the numbers in each end-
point category for each treatment group.Where dichotomous data
were missing, the participants were assumed to have suffered the
least favourable outcome. In studies where a cross-over design was
used, only data from the first treatment period were included.
If trial results were reported as medians and interquartile ranges,
we calculated SDs using the interquartile range (IQR) to provide
the appropriate data to combine the study with other studies.
When two different antidepressants were compared against
placebo (Banerjee 2011), we divided the control group where rel-
evant into two groups approximately evenly among the compar-
isons, with the means and SDs left unchanged. Where it was the
only option, we merged the two treatment groups into one (an-
tidepressant efficacy at three to nine months).
Assessment of risk of bias in included studies
We assessed included trials for risk of bias using the tool in
theCochrane Handbook for Systematic Reviews of Interventions, ver-
sion 5.1.0 (Higgins 2011). We judged whether each trial was at
high, low or unclear risk of bias in each of six domains: sequence
generation, concealment of allocation, blinding, completeness of
outcome data, selective reporting, and funding source.
Measures of treatment effect
For binary outcome data, we calculated the odds ratio for each
trial, and then a pooled odds ratio across appropriate groups of
trials (usingMantel-Haenszel methods). For continuous variables,
we calculated the mean difference between treatment and control
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when each study in themeta-analysis used the same outcome mea-
sure, or the standardised mean difference when the studies used a
variety of outcome measures. We used hazard ratios for time-to-
event data.
Unit of analysis issues
If a trial included multiple treatment groups, then we combined
active treatment groups into one group and control treatment
groups into one group to allow a single pairwise comparison.
Some studies assessed outcomes at multiple time points, so we
pooled data in ranges (e.g. 6 to 13 weeks and 3 to 9 months) to
achieve the best match of time points when combining results with
similar data from different studies.
Dealing with missing data
For each study, we noted what approach had been taken tomissing
data, e.g. imputation, data assumed to be missing at random. We
considered how each method may have contributed to a risk of
bias. We contacted authors of extracted papers for clarification as
required.
Assessment of heterogeneity
We tested for heterogeneity of the treatment effect between the
trials in a meta-analysis using the Chi2 statistic. We quantified
inconsistency using I2 and considered that an I2 value of more
than 40% might represent moderate heterogeneity.
Assessment of reporting biases
If we had been able to include more than 10 studies in any meta-
analysis, then we would have performed a test for funnel plot
asymmetry, looking for small study effects which might indicate
publication bias.
Data synthesis
We pooled data from different trials if we considered that the trials
were sufficiently similar and it was clinically meaningful to do so.
In our primary analyses, we pooled trials of all dementia subtypes
and all types of antidepressants. We also preformed a separate
analysis of antidepressant efficacy at six to nine months.
For dichotomous efficacy outcomes, we used the Mantel-Haen-
szel method, as the study sizes were small. For our tolerability
outcomes, we used the Peto odds ratio method, as for these out-
comes we had larger samples, the intervention effects were rela-
tively small, and the events were not particularly common. If a Chi
2 test and I2 indicated little heterogeneity, we used a fixed-effect
model for meta-analysis. If there was evidence of heterogeneity of
the treatment effect between trials, we either pooled only homo-
geneous results, or used a random-effects model (in which case the
confidence intervals would be broader than those of a fixed-effect
model).
When combining data provided as median and 95% confidence
interval (CI), we used the generic inverse variance method. We
used standard error and median difference.
Subgroup analysis and investigation of heterogeneity
Five of the included studies used an SSRI antidepressant (Petracca
2001; Lyketsos 2003; Rosenberg 2010; Banerjee 2011; An
2017), one mirtazapine (Banerjee 2011), and one venlafaxine (de
Vasconcelos 2007). These are more modern antidepressants com-
monly used in this patient group (as opposed to tricyclic antide-
pressants), so we performed a meta-analysis on these subgroups.
Where it made clinical sense (e.g. when examining tolerability),
we also looked at data by antidepressant group, where possible.
Sensitivity analysis
When looking at treatment efficacy as reflected by depression
symptom rating scale scores, we also performed a sensitivity anal-
ysis only looking at studies that used the Cornell Scale for De-
pression in Dementia (Lyketsos 2003; Rosenberg 2010; Banerjee
2011; An 2017), an instrument specifically developed to measure
depressive symptoms in dementia. As in our main treatment effi-
cacy comparison, some studies only reported completer data, so
we carried out a sensitivity analysis looking at intention-to-treat
data only. We also performed a sensitivity analysis when the ma-
jority of individual studies reported results pointing toward the
opposite of the result of the meta-analysis, or when excluding a
study was considered to reduce imprecision or inconsistency.
Summary of findings
We used the GRADE system to assess the overall quality of evi-
dence behind the effect estimates for each outcome (Ryan 2016).
We downgraded the evidence from ’high-quality’ by one, two, or
three levels after considering imprecision in the effect estimate,
risk of bias in the included studies, inconsistency between studies,
indirectness of evidence, and publication bias. Two review authors
(RD and TD) assessed the quality of evidence independently and
resolved any disagreements.
We presented the amount and quality of evidence in a ’Summary
of findings’ table for the following outcomes: depression (symp-
tom score), depression (response rate), depression (remission rate),
cognitive function, activities of daily living, dropout rate and in-
cidence of adverse events.
R E S U L T S
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Description of studies
Results of the search
Searches carried out in the previous version of the review can be
viewed in Appendix 2.
The searches performed for this update, run in November 2010,
May 2012, March 2013, December 2013, March 2014, Novem-
ber 2014, October 2015, July 2016, and August 2017 retrieved a
total of 827, 1233, 456, 495, 599, 620, 520, 859, and 1304 results,
respectively (Figure 1). The Information Specialist performed a
first assessment to discard obviously non-relevant records and du-
plicates. This left the author team with 43 (November 2010), 49
(May 2012), 27 (March 2013), 36 (December 2013), 31 (Novem-
ber 2014), 22 (October 2015), 40 (July 2016), and 60 (August
2017) results to further assess, from the last two rounds of which
three additional trials were identified (DIADS, Banerjee 2011, and
An 2017).
11Antidepressants for treating depression in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Figure 1. Study flow diagram.
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Included studies
See: Characteristics of included studies (Table 2).
Ten studies with a total of 1592 participants met the inclusion cri-
teria. The studies were generally of short duration (mode: 6 weeks;
mean: 12.7 weeks), although the largest study ran for nearly 10
months (Banerjee 2011). The findings fromone study (DIADS-2)
were reported in separate publications, giving results at 12 weeks
(Rosenberg 2010), and also after an extension phase at 24 weeks
(Weintraub 2010).
All 10 studies stated that the participants met DSM criteria for
dementia or NINCDS-ADRDA criteria for probable Alzheimer’s
disease. The dementia diagnoses in the trial participants were de-
scribed in a variety of ways:
1. An 2017: “Alzheimer’s disease”;
2. Banerjee 2011: “probable Alzheimer’s disease”;
3. de Vasconcelos 2007: “Alzheimer’s disease, vascular
dementia, and mixed dementia”;
4. DIADS-2 (Rosenberg 2010 and Weintraub 2010): “DSM-
IV dementia due to Alzheimer’s disease”;
5. Fuchs 1993: “primary degenerative dementia”;
6. Lyketsos 2003: “probable Alzheimer’s disease”;
7. Petracca 1996: “Alzheimer’s disease”;
8. Petracca 2001: “probable Alzheimer’s disease”;
9. Reifler 1989: “primary degenerative dementia of the
Alzheimer’s type”;
10. Roth 1996: “dementia”.
The mean age of participants who met inclusion criteria in the
studies, excluding one study which only reported the median age
of 80 years (Fuchs 1993), was between 70.8 and 79.3 years, with
an overall mean of 75.37 years.
One Austrian study was conducted among inpatients and nursing
home residents (Fuchs 1993). One multinational study included
both inpatients and outpatients (Roth 1996). The other studies
were conducted in single countries and included only outpatients.
The outpatient settings varied, including neurology outpatient
clinics inArgentina, specialistmemory andother outpatient clinics
in the USA and Brazil, and community mental health teams in
the UK.
The severity of dementia in the studies varied. The mean Mini
Mental State Examination (MMSE) score prior to treatment in
those participants whomet inclusion criteria for the reviewwas be-
tween 16.9 to 23.2 (mean score 19.65). One study, de Vasconcelos
2007, only reported a range of MMSE scores of 10 to 24, and
another, Fuchs 1993, reported a median of 20 and nomean scores.
Six studies stated that the participants met DSM criteria for ma-
jor depression, with one study stating subjects met DSM crite-
ria for either major or minor depression (Petracca 2001). One
study required the presence of depression of at least four weeks’
duration, assessed as potentially needing antidepressants and scor-
ing eight or more on the Cornell Scale for Depression in De-
mentia (CSDD), prior to inclusion (Banerjee 2011). In most
studies, participants were diagnosed clinically, whereas two stud-
ies used a structured clinical interview schedule (Petracca 1996;
Petracca 2001). The DIADS-2 study used specifically adapted
Major Depression Criteria. The papers reporting on this study
(Rosenberg 2010; Weintraub 2010), do not provide validity data
regarding the Major Depression Criteria, but a relevant study,
Teng 2008, reported for the criteria set 100% sensitivity and 66%
specificity for major and 94% sensitivity and 85% specificity for
minor depression,measured against theDSM-IV diagnosis, which
is acceptable.
The older studies used tricyclic antidepressants (TCAs) or related
compounds; four used a selective serotonin reuptake inhibitor
(SSRI); one used a reversible monoamine oxidase inhibitor; and
one a serotonin/noradrenaline reuptake inhibitor. One study had
two active treatment arms, an SSRI and a noradrenergic and spe-
cific serotonergic antidepressant (NaSSA) one (Banerjee 2011).
The doses used in seven studies were within the therapeutic range
for the specificmedication. However, three studies used lower dose
medication (Fuchs 1993; de Vasconcelos 2007; Banerjee 2011, for
mirtazapine).
The studies used a variety of outcome measures. Four studies
used the Hamilton Depression Rating Scale, and four used the
more specific Cornell Scale for Depression in Dementia to mea-
sure changes in depression symptom levels after treatment. One
study used the Montgomery-Asberg Depression Rating Scale and
another used the Geriatric Depression Scale. All included studies
used the Mini-Mental State Examination to assess changes in cog-
nitive functioning. Only five studies deployed one of four different
standardised measures of activities of daily living.
Table 1 summarises the outcome measures included in this review.
Excluded studies
We excluded studies identified by the searches if their subjects
did not have both depression and dementia diagnosed by formal
criteria, the intervention was not an antidepressant or it was given
in combination with another drug, the study was not a treatment
trial or a randomised controlled trial, or change in depression was
not measured.
Ongoing studies
We are not aware of any ongoing studies.
Risk of bias in included studies
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See our ’Risk of bias’ assessment of included studies in Figure 2
and Figure 3.
Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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Figure 3. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
Two studies gave adequate descriptions of the randomisation
method and allocation concealment and we judged them to be at
low risk of bias in both of these domains ( Lyketsos 2003; Banerjee
2011). The other studies stated that they were randomised but did
not describe the methods used for sequence generation or alloca-
tion concealment so we judged the risk of bias to be unclear.
All 10 studies said they were double-blind but only two reported
checking on this. The nature of the placebos was not stated in two
studies (Fuchs 1993; An 2017). In seven studies (Reifler 1989;
Petracca 1996; Petracca 2001; Lyketsos 2003; de Vasconcelos
2007; Rosenberg 2010; Banerjee 2011), drug and placebo were
described as “identical” in appearance, and in one study it was
described as “matched” (Roth 1996). With the exception of two
studies that explicitly checked whether examiners were able to
guess allocation status (Petracca 1996; Rosenberg 2010), there was
insufficient information to permit judgement about the integrity
of blinding, therefore the risk of bias due to performance or de-
tection bias (or both) was rated as unclear in these studies. Study
clinicians correctly guessed allocation status above chance levels in
the active treatment group in one study (Rosenberg 2010), there-
fore we judged this risk of performance bias as high.
Four studies provided intention-to-treat data (Fuchs 1993;
Lyketsos 2003; DIADS-2: Rosenberg 2010 and Weintraub 2010;
Banerjee 2011), three studies only reported completers’ data
(Reifler 1989; Petracca 1996; An 2017), and two studies reported
both types of data (Petracca 2001; de Vasconcelos 2007).We com-
bined these data in the analyses and carried out sensitivity anal-
yses where we considered this to be appropriate. The attrition
rate was very high and unbalanced between groups in three stud-
ies (Banerjee 2011; de Vasconcelos 2007; An 2017), therefore we
rated the attrition bias as high in these studies. InWeintraub 2010,
only 57% of patients were receiving treatment by week 24, there-
fore we rated the risk of attrition bias as high.
We considered three studies to be at high risk of selective reporting
bias (Fuchs 1993; Roth 1996; An 2017). In An 2017, both ITT
and per protocol analyses were performed but only the latter was
reported. The paper also mentioned response and remission analy-
ses in themethods section, but did not report these. The other two
studies reported incomplete data for the depression rating scale
scores (Fuchs 1993; Roth 1996).
Most included studies did not publish enough information for us
to assess risk of bias related to funding; we considered one study
to have low risk of bias (Banerjee 2011), one study to have high
risk of bias (Roth 1996), and the rest to have unclear risk of bias.
Effects of interventions
See: Summary of findings for the main comparison
Antidepressant treatment compared with placebo for depression
in dementia
See antidepressant versus placebo comparisons in Data and
analyses, and Summary of findings for the main comparison.
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We included 10 included studies with a total of 1592 participants.
Two studies published results for trial completers but did not in-
clude the numbers in each treatment group who had completed
(Fuchs 1993; Roth 1996). Therefore we were only able to use
adverse events data from both of these studies. One study had a
cross-over design and we used data from the first treatment period
only (Petracca 1996). Only one study used the Montgomery-As-
berg Depression Rating Scale ( MADRS) ( de Vasconcelos 2007).
One study reported outcomes using both the Cornell Scale for
Depression in Dementia (CSDD) and the Hamilton Depression
Rating Scale (HAM-D) (Lyketsos 2003); when pooling data from
all studies, we used the CSDD data from this study.
We pooled data separately for outcomes reported at 6 to 13 weeks
and 24 to 39 weeks (6 to 9 months). Two studies contributed
data to both time point analyses (DIADS-2: Rosenberg 2010;
Weintraub 2010, 12 and 24 weeks; Banerjee 2011, 13 and 39
weeks).
Treatment efficacy
The analyses concerning efficacy included eight studies (An 2017;
Banerjee 2011; de Vasconcelos 2007; Lyketsos 2003; Petracca
1996; Petracca 2001; Reifler 1989; Rosenberg 2010), with a total
of 614 subjects.
Depression (measured by rating scales)
We found that there was little or no effect of antidepressant treat-
ment on depression measured with symptom scales after 6 to
13 weeks of treatment, compared to placebo (standardised mean
difference (SMD) -0.10, 95% confidence interval (CI) -0.26 to
0.06; 614 participants; 8 studies; I2 = 7%; Analysis 1.1; Figure
4). Although this analysis included treatment with different types
of antidepressants, heterogeneity was low and we considered the
evidence to be of high quality. Two of the studies included in
this meta-analysis only reported completers’ data ( Reifler 1989;
Petracca 1996), therefore we carried out a sensitivity analysis ex-
cluding these studies. The result, now based entirely on intention-
to-treat data, was unchanged and indicated little or no difference
between antidepressant and placebo treatment ( SMD -0.10, 95%
CI -0.27 to 0.07, P = 0.24). It is of note that the two studies ex-
cluded in the sensitivity analysis ( Reifler 1989; Petracca 1996),
investigated the effect of tricyclic antidepressants (TCAs) (drugs
not commonly used in this population).
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Figure 4. Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.1 Depression endpoint
mean scores at 6-13 weeks.
Two studies assessed outcomes after a longer treatment period:
after 24 weeks, DIADS-2 (Weintraub 2010), and after 39 weeks
(Banerjee 2011). Both measured depressive symptoms using the
CSDD.We found that there was probably little or no effect of this
more prolonged treatment on depressive symptoms (mean differ-
ence (MD) 0.59 point, 95% CI -1.12 to 2.3, 357 participants;
Analysis 1.2). Heterogeneity was low (I2 = 0%), but we considered
this moderate-quality evidence due tomethodological limitations,
as both studies had a high attrition rate and one study (DIADS-
2) also had a high risk of bias related to blinding.
We looked separately at results from the studies which assessed de-
pressive symptoms after 12 or 13 weeks using theCSDD (Lyketsos
2003; the DIADS-2 study in Rosenberg 2010; and Banerjee
2011). An analysis of the findings from these three studies indi-
cated little or no benefit from treatment with an antidepressant
(MD -0.10 point, 95%CI -0.99 to 0.78; 433 participants; 3 stud-
ies; Analysis 1.2).
In a pooled analysis of the four studies which used the Hamilton
Depression Rating Scale (Reifler 1989; Petracca 1996; Petracca
2001; Lyketsos 2003), there was little or no difference between
placebo and antidepressant after 6 to 12 weeks of treatment (MD
-0.85, 95% CI -2.65 to 0.95; participants = 134; studies = 4; I2 =
24%; Analysis 1.3).
The only study using the Montgomery-Asberg Depression Rating
Scale, de Vasconcelos 2007, reported no significant difference in
mean score changes.
A subgroup analysis of the five studies using a selective serotonin
reuptake inhibitor (SSRI) showed little or no difference between
the antidepressant and placebo groups (SMD -0.13, 95%CI -0.33
to 0.07; 400 participants; 5 studies; I2 = 42%; see 1.1.1 in Analysis
1.1). There was moderate heterogeneity in the data, but neverthe-
less, we considered this overall to be high-quality evidence.
Depression (measured by rates of response or remission)
We also sought to examine rates of response and remission from
depression. “Response” was defined as “partial response” by best
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clinical judgment rated by two psychiatrists (Lyketsos 2003), 50%
or more reduction in HAM-D scores (Petracca 2001), or a mod-
ified Alzheimer’s Disease Cooperative Study Clinical Global Im-
pression of Change (mADCS-CGI) rating of 2 or less (Weintraub
2010). Data on response to treatment after 6 to 12 weeks came
from two studies using an SSRI ( Petracca 2001; Lyketsos 2003).
Theremay be a higher response rate among participants on antide-
pressants than on placebo (odds ratio (OR) 2.42, 95% CI 0.97 to
6.09; 85 participants; 2 studies; I2 = 0%; Analysis 1.4.1; Figure 5),
but there is a lot of uncertainty about this result, which is also con-
sistent with little or no effect. We considered this evidence to be
low-quality, due to indirectness (the definitions of “response” were
different in the studies and some could be considered surrogate
measures, e.g. “best clinical judgement”) and imprecision (com-
parison was underpowered due to low numbers of participants). A
third study, de Vasconcelos 2007, used 50% or more reduction in
MADRS scores as a definition of remission as opposed to response,
but to be consistent with other studies we also included their data
in our meta-analysis of response rates. When we added this third
study (Analysis 1.4), the result remained imprecise with uncer-
tainty about the direction and size of the effect (OR 1.71, 95%
CI 0.80 to 3.67; 116 participants; 3 studies; I2 = 13%). Only one
study (DIADS-2: Weintraub 2010) provided longer-term data on
response. The result was imprecise so the effect of antidepressants
after 24 weeks was uncertain (OR 1.45, 95% CI 0.72 to 2.92; 131
participants; 1 study; I2 = 0%).
Figure 5. Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.4 Number of responders
(ITT) at 6-12 weeks.
“Remission” was defined by the authors of the studies as a HAM-
D score of seven or lower (Petracca 1996), a HAM-D score of
seven or lower and Clinical Global Impression rating of one or
two (Petracca 2001), “full response” rated by two psychiatrists’
best clinical judgment (Lyketsos 2003), or a mADCS-CGI rating
of two or lower and a CSDD score of six or lower (DIADS-2:
Rosenberg 2010, Weintraub 2010). Although with the exception
of the smallest study (Petracca 1996), there was no significant dif-
ference in remission rates between the antidepressant and placebo
treated groups reported in individual studies, a meta-analysis indi-
cated that at 6 to 12 weeks remission rates favoured antidepressant
over placebo (OR 2.57, 95% CI 1.44 to 4.59; 240 participants;
4 studies; I2 = 0%; Analysis 1.6; Figure 6). We regarded this as
moderate-quality evidence due to indirectness (i.e. definitions of
“remission” were different in the studies and some could be con-
sidered surrogate measures, e.g. “best clinical judgement”). A sub-
group analysis of the SSRI studies indicated that remission rates
were higher in the antidepressant group than in the placebo group
(OR 2.22, 95% CI 1.20 to 4.12; 216 participants; 3 studies; I
2 = 0%; Analysis 1.6), based on evidence graded as low-quality
due to indirectness and imprecision (comparison was underpow-
ered due to low number of participants). Again, only one study
(DIADS-2: Weintraub 2010) provided longer term data and the
result was imprecise so the effect of antidepressants on remission
after 24 weeks is uncertain (OR 1.75, 95% CI 0.80 to 3.82; 131
participants; 1 study; Analysis 1.7).
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Figure 6. Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.6 Number of patients
with remission (ITT) at 6-12 weeks.
Cognitive function
Meta-analyses of cognitive function measured with theMiniMen-
tal State Examination (MMSE) showed that there was probably
little or no difference between antidepressant or placebo at weeks
6 to 12, whether the outcome was endpoint mean scores (MD
0.33 point, 95% CI -1.31 to 1.96; 194 participants; 5 studies; I2 =
0%; Analysis 1.8) or change in mean scores (MD 0.19 point, 95%
CI -0.81 to 1.19; 5 studies; Analysis 1.9). This was also true in
sensitivity analyses looking at endpoint intention-to-treat (ITT)
data (Petracca 2001; Lyketsos 2003: MD -0.76 point, 95% CI -
3.78 to 2.27, P = 0.62) or completers-only data (Reifler 1989;
Petracca 1996; Petracca 2001: MD -0.34 point, 95% CI -3.06 to
2.39; P = 0.81; analysis not presented). We regarded this as mod-
erate-quality evidence due to imprecision (relatively few partici-
pants and wide confidence intervals). There was also no evidence
of a difference between groups at six to nine months for endpoint
mean scores (MD 1.00 point, 95% CI -1.14 to 3.14; 131 partici-
pants; 1 study; see Analyis 1.7.2) or change in mean scores (MD -
0.38 point, 95% CI -1.90 to 1.13; 2 studies; Analysis 1.9) on the
MMSE.
Activities of daily living
Five studies measured performance of activities of daily liv-
ing (ADLs) using different scales (Reifler 1989; Petracca 1996;
Petracca 2001; Lyketsos 2003; An 2017). We were able to pool
data from four studies to estimate a standardised mean difference
between groups; we had to exclude the data from Petracca 1996,
because they were available only as change-from-baseline while
the other studies reported endpoint scores. There was little or no
difference between antidepressants and placebo as regards ADLs
at weeks 6 to 13 (SMD -0.05, 95% CI -0.36 to 0.25; 173 partic-
ipants; 4 studies; I2 = 20%; Analysis 1.10, Figure 7). We consid-
ered this to be high-quality evidence. The only study that reported
data at six to nine months (Weintraub 2010) did not indicate any
difference between groups either.
Figure 7. Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.10 Activities of daily
living, endpoint values at 6-13 weeks.
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Quality of life
We could not pool the results on quality-of-life outcomes from two
studies (Weintraub 2010; Banerjee 2011), as they reported data
in very different formats. Neither study reported any significant
difference by treatment group.
Dropouts and adverse effects
Tolerability (measured as withdrawal from trial)
Data from nine studies indicated that participants on antidepres-
sant treatment were probably more likely to drop out of the study
over 6 to 13 weeks (OR 1.51, 95% CI 1.07 to 2.14; 836 partici-
pants; 9 studies; I2 = 0%; Analysis 1.12; Figure 8). We graded this
evidence as moderate-quality due to imprecision. Subgroup anal-
yses looking at SSRIs, venlafaxine, mirtazapine, and older antide-
pressants separately found that placebo was consistently favoured,
but the results for the individual antidepressants were associated
with more uncertainty and in each case were also consistent with
little or no difference between groups. There was no clear evidence
of a difference between groups after six to nine months (OR 1.25,
95% CI 0.83 to 1.88; 457 participants; 2 studies; Analysis 1.13),
on the basis of evidence rated as moderate-quality due to impre-
cision.
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Figure 8. Forest plot of comparison: 1 Antidepressant versus placebo, outcome: 1.12 Tolerability: Number
of dropouts at 6-13 weeks.
Safety (measured by the incidence of adverse effects)
Participants taking an antidepressant were probably more likely
to experience at least one adverse event at 6 to 13 weeks (Peto
OR 1.55, 95% CI 1.21 to 1.98; 1073 participants; 3 studies; I
2 = 26%; Analysis 1.14), although we considered the evidence to
be moderate-quality due to publication bias. This effect was more
pronounced with SSRIs and older antidepressants, whilst the Peto
OR in the mirtazapine data was not significant. There were statis-
tically significant differences in favour of placebo for numbers of
participants experiencing dry mouth (PetoOR1.80, 95%CI 1.23
to 2.63; 1044 participants; 5 studies; I2 = 55%; Analysis 1.15) and
dizziness (Peto OR 2.00, 95% CI 1.34 to 2.98; 1044 participants;
5 studies; I2 = 29%; Analysis 1.18). We rated the evidence for both
these outcomes as high-quality. Subgroup analyses revealed similar
patterns with SSRIs and older antidepressants for both outcomes.
There were no statistically significant differences found for fatigue
(quality of the evidence rated as low due to selective reporting and
imprecision; Analysis 1.16) or constipation (quality of evidence
rated as moderate due to imprecision; Analysis 1.17).
Data on serious adverse events (SAEs) were reported in a num-
ber of the included studies but unfortunately in different formats,
therefore they could not be pooled. Banerjee 2011, which looked
at data at 13 weeks, reported 15 SAEs in the placebo group, 12 in
the sertraline group, and 14 in themirtazapine group; out of these,
3, 8, and 10 were severe, respectively, suggesting that although the
overall number of SAEs did not differ between groups, more of
these events were severe in those participants on antidepressants
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compared with placebo. Over 24 weeks in the DIADS-2 study
(Weintraub 2010), SAEs occurred in 27.3% of participants on
sertraline compared with 12.7% of those on placebo. Petracca and
colleagues reported serious side effects in one participant who was
in the group treated with an antidepressant (Petracca 2001); and
in Roth 1996, 27.4% of the adverse events were rated as severe
in the placebo group compared with 29% in the moclobemide
group (however it should be noted that their “safety” population
included both participants with dementia with depressive symp-
toms and those with depression with cognitive decline). Overall,
it seems that SAEs occurred more often in those participants given
antidepressants compared to those on placebo.
D I S C U S S I O N
Summary of main results
Meta-analyses of outcome measures relating to antidepressant
treatment efficacy revealed little or no effect of antidepressants on
depression rating scale mean scores at 6 to 12 weeks (high-quality
evidence) or at 6 to 9 months (moderate-quality evidence). There
was also no clear evidence of an effect of treatment on the number
of responders (low-quality evidence). We found moderate-quality
evidence favouring antidepressants in the comparison of remission
rates at 6 to 12 weeks, but the result at 24 weeks was imprecise
and we could not be sure that the difference was maintained.
Subgroup analyses looking at selective serotonin reuptake in-
hibitors (SSRIs), venlafaxine, mirtazapine, and tricyclic antide-
pressants (TCAs) separately did not indicate differences between
these subgroups. A sensitivity analysis looking at studies which
measured depression with the Cornell Scale for Depression in De-
mentia (CSDD), which is designed specifically to assess depres-
sion in dementia, found little or no effect of antidepressants when
compared to placebo.
There was little or no difference in measures of cognitive function
(Mini Mental State Examination (MMSE) scores) or activities of
daily living between antidepressant andplacebo groups (moderate-
and high-quality evidence, respectively).
Participants taking antidepressants were probably more likely to
drop out of treatment and more likely to experience at least one
adverse event over 6 to 12 weeks. Patients on antidepressant were
significantly more likely to experience dry mouth or dizziness, but
not fatigue or constipation.
Overall completeness and applicability of
evidence
The process of combining data from differing studies is problem-
atic. The assumption is that the study samples are drawn from
similar populations but the validity of this assumption is difficult
to assess. The adherence to the inclusion criteria for studies ensures
some homogeneity in that all participants included in the review
meet recognised criteria for both depression and dementia.
As discussed earlier, the relationship between depression and de-
mentia is complex, and depression is more difficult to diagnose
in patients with dementia. DSM criteria for depression include
anhedonia and poor concentration, which are both symptoms of
dementia. Some studies attempted to take this potentially con-
founding factor into account when making the diagnosis of de-
pression (Lyketsos 2003; Rosenberg 2010; Banerjee 2011). A fur-
ther concern is that only one of the depression rating scales used
in the included studies was developed for the specific purpose of
measuring depression in dementia (CSDD). Other instruments
used in the included studies were developed in younger subjects
and may underestimate depression in older patients because of
the atypical nature of depression in older people (e.g. the Hamil-
ton Depression Scale, HAM-D). Even where scales are designed
specifically for the older population, they may not be reliable in
the specific scenario of depression in dementia (e.g. the Geriatric
Depression Scale) (Burns 2002). Assessing response to treatment
and remission is also fraught with difficulties in these patients.
Depression and dementia are both highly heterogeneous condi-
tions. Patients with mild dementia who are unhappy at the threat
to future independence which their diagnosis represents, may be
different from those with a MMSE of 15, apathy, anhedonia, low
mood and intermittent anxiety. Theoretically, this difference has
the potential to obscure potentially useful benefits of antidepres-
sants in patient subgroups. There was no important heterogeneity
in our meta-analysis. However, this might be because all studies
examined patients with a wide range of MMSE scores. It should
therefore be regarded as absence of evidence rather than evidence
of absence.
We only included studies using formal criteria for depression to
improve the reliability and clinical applicability of our findings,
thereby including the more severe end of the depressive spectrum
which is more likely to respond to antidepressant treatment.
It cannot be excluded that adjuvants (e.g. lithium or antipsy-
chotics) or combination treatments (not studied in this review)
could show a significant effect in the treatment of patients with
depression in dementia.
It is of note that activities of daily living and especially dementia-
specific quality-of-life measures have only been used in the more
recent studies.
Quality of the evidence
As presented in the ’Risk of bias’ and ’Summary of findings’ tables,
the quality of the evidence for most outcomes was of moderate-
or low-quality principally due to risk of bias and imprecision.
The analysis of adverse event data in these studies was particu-
larly difficult due to a number of factors. There was considerable
heterogeneity in the reporting of adverse events across the stud-
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ies in terms of comprehensiveness, mode of ascertainment, and
format. Some studies reported all or nearly all side effects and
adverse events, some grouped these into systems (e.g. respiratory
system, gastrointestinal system, etc.), some only reported serious
adverse events, and some a mixture of these. Ideally, figures for all
categories should be reported in order that results from different
studies (often using different medications) can be meta-analysed.
The studies also differed in terms of whether they relied on spon-
taneous reporting or various types of questioning. Some reports
included the total number of adverse events, others only published
the number (or percentages) of participants reporting side effects,
or those who withdrew from the study due to adverse events. Tol-
erability ratings (very good, good, etc.) presented by the investi-
gator appear a subjective measure. Only one study made explicit
reference to accepted guidelines in how the authors defined serious
adverse events (SAEs) (Rosenberg 2010). They used the Food and
Drug Administration definition, i.e. any adverse drug experience
occurring at any dose that resulted in any of the following: death,
a life-threatening adverse experience, inpatient hospitalisation or
prolongation of existing hospitalisation, or persistent or signifi-
cant disability/incapacity. Following a set of consistent guidelines
on reporting would significantly enhance the reliability of the ev-
idence base.
Potential biases in the review process
It is unfortunate that the results of two of the ten studies (Fuchs
1993, Roth 1996) included in this update could not be included in
the efficacy meta-analysis, as they did not include the numbers in
each treatment group who had completed the study. The authors
of the studies were contacted and statistical elaboration requested,
but for various reasons elaboration did not prove possible. This
is of particular regret with regards to Roth 1996, as it was a large
multi-centre studywith 476participantsmeeting inclusion criteria
for the review and the authors reported positive results. It is a
limitationof our study that in order to be able to enter the sertraline
andmirtazapine arms of Banerjee 2011, we had to split the control
group into two groups which remained correlated.
We used endpoint data as opposed to change from baseline, as the
latter are often not reported and calculating the standard deviation
from the reported data is problematic.
It is also possible that our study has failed to find an effect that
really exists (type 2 error). We argue that this possibility is less
likely, as we have minimised the amount of data manipulation and
simply combined symptom scores; therefore unwitting biases are
less likely to have emerged.
Agreements and disagreements with other
studies or reviews
Other reviews of this subject have been published. A review by
Starkstein and colleagues, Starkstein 2006, drew attention to two
individual studies that are also included in our analysis (Roth 1996;
Lyketsos 2003), and reported efficacy in the treatment of depres-
sion in dementia with sertraline and moclobemide, respectively.
A systematic review by Thompson and colleagues concluded that
antidepressants were efficacious (Thompson 2007). This review
examined antidepressants in Alzheimer’s disease rather than just
in dementia as a whole but this difference is unlikely to have been
important, as the authors included four of the same studies that
we have used here (Reifler 1989; Petracca 1996; Petracca 2001;
Lyketsos 2003). The fifth study used byThompson and colleagues,
Magai 2000, was excluded from our review because only 10% of
the sample had diagnosed major depression and we felt the validity
of the diagnosis of depression was questionable and not compara-
ble with other studies, considering that they had to rely on proxy
measures in a patient population much more severely demented
than in the other studies included. Proxy measures included cut-
off scores on the Cornell Scale and the Gestalt Depression Scale
(Greenwald 1991), and also analysis of facial expression. Thomp-
son and colleagues adopted a different approach, namely to define
cases as responders on the basis of a 50% reduction in their depres-
sion scores (HAM-D or other) or as achieving remission (HAM-D
score of less than eight, or equivalent) (Thompson 2007). How-
ever, the authors also went on to state that: “Other definitions
of depression remission or response were considered if they were
deemed clinically valid and (or) relevant”. In contrast, we have
looked at depression scores as continuous variables as well as ex-
amining response and remission. Introducing criteria for response
and remission carries the possibility of introducing a bias in favour
of treatment (type 1 error). In their narrative review, Farina and
colleagues also concluded that antidepressants are not effective for
depression (Farina 2017).
Another review, which included the deVasconcelos andRosenberg
studies (both of which reported lack of efficacy) in addition to the
same ones included in the Thompson review, was in accordance
with our findings (Nelson 2011). A meta-analysis by Sephery and
colleagues, Sepehry 2012, found a lack of efficacy for antidepres-
sants based on data from five studies. Several other recent reviews
also noted the limited evidence and concluded that more studies
were needed (Modrego 2010; Saarinen 2010;Haight 2013; Leong
2014; Orgeta 2017).
Our findings are also somewhat different to some other reviews
regarding drug safety. The Thompson review reported dropouts
from treatment due to all causes and due to adverse events, but
did not examine individual symptoms. From this relatively broad
approach, they found no significant differences. However, we have
analysed data regarding several side effects and found that partici-
pants treated with antidepressants experienced significantly more
adverse events. It should be noted that three studies that con-
tributed to this analysis were not available to Thompson and col-
leagues (the Banerjee, de Vasconcelos, and DIADS-2 studies).
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A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Although depression is common in people with dementia and
many patients are prescribed antidepressants, there is limited pub-
lished evidence to support the efficacy of antidepressants for the
treatment of depression in this patient group. They do not improve
outcomes on depression rating scales, although there is moderate-
quality evidence to show that they probably increase short-term
remission rates. There is also moderate-quality evidence that they
are associated with more adverse effects than placebo. Although
we did not find differential effects of different antidepressants,
these subgroup data were sparse. It is possible that patients with
different clinical characteristics (subtypes or severities or dementia
or depression) may respond differently.
Implications for research
With an expanding ageing population and a resultant increase in
the prevalence of dementia, more research is needed in this impor-
tant clinical area. There is a need for well-conducted randomised
controlled trials, using scales validated in older people with de-
pression and dementia (such as the Cornell Scale for Depression
in Dementia), of modern, frequently used drugs and sufficient
sample sizes that would allow a study of treatment response and
detailed adverse event profile according to dementia aetiology and
severity and depression severity.We would recommend that future
research explores narrower spectra of cognitive impairment and
more specific subsyndromes of affective disturbance in dementia.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
An 2017
Methods 12-week randomised, double-blind, placebo-controlled multi-centre trial with open-
label, 12-week extension
Participants Country: South Korea
Setting: 6 dementia centres
Recruitment: prospective subjects
Numbers: 84 (42 in each group; 91 were screened)
Inclusion criteria:
1. over the age of 50;
2. diagnosed with Alzheimer’s disease in accordance with NINCDS-ADRDA
criteria;
3. three or more symptoms of the Olin depression (major depressive episode)
diagnostic criteria;
4. clinical dementia rating (CDR) of 0.5 to 2;
5. MMSE 10 ~ 26 (K-MMSE);
6. GDS-15 ≥ 5 points;
7. care giver spending at least 4 hours a day, 3 days a week with the participant
accompanying them to each visit.
Exclusion criteria:
1. antidepressant treatment within 4 weeks before the start of the trial;
2. other mental illness;
3. serious medical illness;
4. organic brain disease or organic affective disorder;
5. taking memantine;
6. habitual drinking or a history of drug abuse.
Interventions 5mg/day of escitalopram, increased 5 mg/day every two weeks, up to a maximum dosage
of 15 mg/day, which was maintained over 8 weeks, unless the participant experienced
medication side effects
Outcomes Assessments from the first 12 weeks were used to measure efficacy, whereas data from
all 24 weeks were included in safety analysis. Efficacy analysis was done using both
intention-to-treat (ITT) and per-protocol (PP) populations, which were specified before
subject enrolment. Only the PP analysis reported
Efficacy measures:
1. Cornell Scale for Depression in Dementia (CSDD) and GDS-15 every 4 weeks
during the double blind phase;
2. based on CSDD scores, response was categorized into ‘No response’, ‘Partial
response’ (score reduction ≥ 25%), and ‘Full response’ (score reduction ≥ 50%);
3. K-MMSE, CDR, ADAS-Cog, and Seoul Instrumental Activities of Daily Living
(SIADL), Neuropsychiatric Inventory Questionnaire (NPIQ) and Pittsburgh Sleep
Quality Index (PSQI) at 12 weeks.
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An 2017 (Continued)
Notes Due to the way adverse event data were reported, we were only able to include these data
in one of our outcomes. We have requested the completers’ data from the authors, but
have not received a reply to date
This studywas sponsored byKonkukUniversityMedical Center and supported byDong-
a ST, a pharmaceutical manufacturer specializing in CNS drugs. One of the authors
(Do-Hoon Kim) made a disclosure of receiving grants from various pharmaceutical
companies and lecture fees from Rundbeck (sic). (NB, Lundbeck is the manufacturer of
escitalopram.)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No detail provided
Allocation concealment (selection bias) Unclear risk No specific detail provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The trial registration mentions double
masking under design, including partici-
pant and investigator, however, no details
are provided about the placebo
Incomplete outcome data (attrition bias)
All outcomes
High risk Twenty-four patients were unable to finish
the study (the authors refer to this as 30%,
our calculation is a little lower: 24/84 = 28.
6%), 40% more in the escitalopram than
in the placebo group (14 vs 10), the differ-
ence being largely due tomore people with-
drawing consent in the escitalopram group
Selective reporting (reporting bias) High risk Efficacy analysiswas done using both inten-
tion-to-treat (ITT) and per-protocol (PP)
populations, which were specified before
subject enrolment. The published report
only included the results of the PP analy-
sis, arguing that “treatment response could
be more reliably assessed and the popula-
tion would be less heterogeneous than the
ITT population”. Partial and full response
were not prespecified outcomes in the pro-
tocol available on Clinicaltrials.gov but de-
scribed in the data analysis section of the
report (NB, these outcomes were eventu-
ally not reported in the results section of
the An 2017 paper).
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An 2017 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The trial registration mentions double
masking under design, including partici-
pant and investigator, however, no details
are provided about the placebo
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The trial registration mentions double
masking under design, including partici-
pant and investigator, however, no details
are provided about the placebo
Banerjee 2011
Methods Placebo-controlled, parallel group, double-blind, randomised, pragmatic trial
Follow-up at 13 and 39 weeks
Participants Country: United Kingdom, multi-centre (9 centres in England)
Setting: outpatients
Number: 326
Inclusion criteria: NINCDS/ADRDA criteria for probable and possible Alzheimer’s
disease and co-existing depression with CSDD score > 8 (nearly all met criteria for
categorical diagnosis of depression in Alzheimer’s disease as perOlin’s criteria (Olin 2002)
Exclusion criteria: clinically too critical for randomisation (e.g. suicide risk), absolute
contraindication to trial medication, currently taking antidepressant, being in another
trial, and having no family or professional carer to give collateral information
Interventions 1. sertraline (target dose: 150 mg/day)
2. mirtazapine (target dose: 45 mg/day)
3. placebo
(1:1:1 allocation)
Outcomes Co-primary outcomes:
1. Cornell Scale for Depression in Dementia (CSDD);
2. costs measured by the Clients Service Receipt Inventory (CSR at 13 weeks
analysed according to an intention to treat (ITT) approach.
Secondary outcomes and moderators:
1. disease-specific health-related quality of life (DEMQOL and DEMQOL-Proxy);
2. generic quality of life (EQ-5D interview administered to the carer);
3. withdrawal from treatment;
4. cognitive impairment (MMSE);
5. medication adherence;
6. adverse events;
7. carer mental health (General Health Questionnaire; GHQ-12);
8. carer quality of life (SF-12v2);
9. carer burden (Zarit Scale);
10. behavioural disorder (Neuropsychiatric Inventory; NPI);
11. dementia vascularity index (modified Hachinksi Scale) at baseline.
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Banerjee 2011 (Continued)
Notes Due to a call for extra funding following slower recruitment than predicted, the sample
size needed (N = 507) was re-assessed and a revised target of N = 339 (113 in each group)
was set
The study was funded by the UK National Institute of Health Research Health Tech-
nology Assessment programme. Most authors acknowledged receiving consultancy fees,
speakers’ fees, research funding, or educational support to attend conferences from com-
panies involved in themanufacture of antidepressants and anti-dementia drugs. Two had
been employed by the UK Department of Health and one by the Alzheimer’s Society
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Allocation to sertraline, mirtazapine, or
placebo in a 1:1:1 ratio by clinical trials unit
at King’s College London. Random allo-
cation stratified by centre with computer-
generated sequence with randomly varying
block sizes of 3 or 6
Allocation concealment (selection bias) Low risk The Mental Health & Neuroscience Clin-
ical Trials Unit (CTU) database program-
mer independently undertook treatment
allocation. Further description of the allo-
cation is not available
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Participants aiming to take 6 tablets orally
once a day (up to three sertraline 50 mg or
sertraline placebo and up to three mirtaza-
pine 15 mg or mirtazapine placebo, with
the placebo looking identical in appearance
for each antidepressant). The authors state
that “referring clinicians and researchwork-
ers completing baseline and follow-up as-
sessments were kept blind to group alloca-
tion as were patients and pharmacies”, but
no checks as to whether patients or asses-
sors could guess allocation status are men-
tioned. Statisticians were blind to group
identity until after the analyses were com-
pleted. The statistician performing the fi-
nal analyses was not involved in the re-as-
sessment of the sample size
Incomplete outcome data (attrition bias)
All outcomes
High risk “Analyses were pragmatic and based
on the intention-to-treat sample.” Al-
though, overall, adequate sample sizes were
achieved in each group, by week 39, 24%
of those on placebo, 35% of those on ser-
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Banerjee 2011 (Continued)
traline, and 29% of those on mirtazapine
were withdrawn from the trial. Those on
sertraline had a clearly higher attrition rate.
For 2 patients in each group incomplete
data were collected
Selective reporting (reporting bias) Unclear risk Drug adherence which was a prespecified
secondary outcome measure was not re-
ported
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Participants aiming to take 6 tablets orally
once a day (up to three sertraline 50 mg or
sertraline placebo and up to threemirtazap-
ine 15 mg or mirtazapine placebo, with the
placebo looking identical in appearance for
each antidepressant). The authors state that
“referring clinicians and research workers
completing baseline and follow-up assess-
ments were kept blind to group allocation
as were patients and pharmacies”, but no
checks as to whether patients or assessors
could guess allocation status are mentioned
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors state that “referring clinicians
and research workers completing baseline
and follow-up assessments were kept blind
to group allocation as were patients and
pharmacies”, but no checks as to whether
patients or assessors could guess allocation
status are mentioned. Statisticians were
blind to group identity until after the anal-
yses were completed. The statistician per-
forming the final analyses was not involved
in the re-assessment of the sample size
de Vasconcelos 2007
Methods Placebo-controlled, double-blind, randomised, flexible dose
Participants Country: Brazil
Setting: outpatients
Recruitment: unclear
Number: 31 patients with dementia and depression (41 approached, 10 excluded due
to clinical co-morbidities or insufficient caregiver support)
Inclusion criteria: DSM-IV for dementia and depression, MMSE, Cornell Scale for
Depression in Dementia
Exclusion criteria: severe dementia (MMSE <= 10), suicidal, illusional, delirious, no
caregiver to assure compliance, unstable medical condition during screening, psychiatric
condition other than dementia and depression
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de Vasconcelos 2007 (Continued)
Interventions 1. venlafaxine (range: 37.5-131.25 mg/day; mean: 75 mg/day)
2. placebo
Outcomes 1. Response rate (remission defined as at least 50% reduction in MADRS score)
2. Montgomery-Asberg Depression Rating Scale (MADRS)
3. Clinical Global Impressions
4. Analysed at week 1 and week 6 according to “last observation carried forward
(LOCF)” and “per protocol” approach; ANCOVA with baseline score as a covariate
5. Safety and tolerability assessed as per adverse events and dropouts
Notes AChEIs (acetylcholinesterase inhibitors, the most commonly used group of dementia
medications) were not permitted
Funding was not specifically mentioned.
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information is given on how randomi-
sation was carried out
Allocation concealment (selection bias) Unclear risk Not enough detail is given on allocation
concealment.
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The authors do not provide details on dou-
ble blinding (e.g. assessor status was not
given), although they say that the venlafax-
ine and the placebo tablets were identical
in appearance and patients received a fixed
number of tablets
Incomplete outcome data (attrition bias)
All outcomes
High risk 41 patients were approached; 10 were not
included due to “clinical co-morbidities
and insufficient carer support”. Out of the
31 patients enrolled, there were 9 dropouts
(lost to follow-up: 1 and 1, withdrawals:
2 and 0, and adverse events: 3 and 2 in
the venlafaxine and placebo groups, respec-
tively. Both “intention-to-treat last-obser-
vation-carried-forward” (N = 31) and “per
protocol” (N = 23) approaches are reported
Selective reporting (reporting bias) Unclear risk The figures in the table do not match the
data in the text in the reporting on causes
of dropouts and adverse events
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de Vasconcelos 2007 (Continued)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors do not provide details on dou-
ble blinding (e.g. assessor status was not
given), although they say that the venlafax-
ine and the placebo tablets were identical
in appearance and patients received a fixed
number of tablets
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk The authors do not provide details on dou-
ble blinding (e.g. assessor status was not
given)
Fuchs 1993
Methods Randomised (“randomly assigned”, no further details), double-blind, placebo controlled,
parallel group, 8 weeks duration
Participants Country: Austria
Setting: 5 centres, inpatients (geriatric wards) and nursing home
Number: 127 (72 female (57%) and 55 male (43%))
Inclusion criteria: DSM-III-R for primary degenerative dementia and depression, onset
at age > 65 years, any severity
Exclusion criteria: need for antidepressant therapy
Interventions 1. Maprotiline 25-75 mg/day (mean max dose 59 mg)
2. Placebo
Outcomes Geriatric Depression Scale (GDS)
MMSE
global impression by video rating (primary parameter)
Notes Problems
1. No information on the numbers of participants in the antidepressant and placebo
groups included in the analyses of the MMSE and GDS scores (MMSE: 50 patients
scored greater than 24 on baseline therefore not demented according to baseline or
there were no MMSE data available, therefore these 50 were not analysed for the
MMSE. GDS: 36 patients with either a baseline of less than 5 or without any GDS
data were not included in the GDS analysis.)
2. 6 protocol violators under the age of 65 included in the analysis.
3. Patients “in need of antidepressant therapy” were excluded (therefore the group
were mildly depressed).
A. Fuchs’ affiliation was Ciba-Geigy AG, Basel, Switzerland. The authors acknowledge
assistance from workers of Ciba-Geigy during all stages of the study
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Unclear risk Not reported
Allocation concealment (selection bias) Unclear risk Not reported
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk Referring to the video ratings, the authors
state “any content which could possibly de-
stroy the blindness of the raters with regard
to the date of recording were cut out by
an independent technician”, however, no
mention is made about who assessed and
recorded the adverse events (only this data
was used from this study in this review)
Incomplete outcome data (attrition bias)
All outcomes
Low risk 33 patients discontinued the study before
completing 8 weeks of treatment (lack of
tolerability: 1 and 1, lack of compliance: 2
and 1, other reasons [intercurrent disease,
transfer to other hospital, return home,
etc] 16 and 12 in the maprotiline and
placebo groups, respectively). Attrition in
the maprotiline and placebo groups was
comparable and acceptable
Selective reporting (reporting bias) High risk 50 patients had an MMSE score greater
than 24 or missing data and therefore
were not analysed for their MMSE scores.
36 patients had a baseline of less than
5 points on the GDS or missing GDS
data and therefore were not analysed for
GDS scores. Although the authors present
MMSE and GDS means for the maproti-
line and placebo groups, it was not possible
to know how many patients there were in
each group. Therefore, only adverse events
data could be included from this study into
our review. This however included all par-
ticipants, including those who had higher
than the cut-off on the MMSE or lower
than the cut-off on the GDS
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Referring to the video ratings, the authors
state “any content which could possibly de-
stroy the blindness of the raters with regard
to the date of recording were cut out by
an independent technician”, however, no
mention is made about who assessed and
recorded the adverse events (only this data
was used from this study in this review)
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Referring to the video ratings, the authors
state “any content which could possibly de-
stroy the blindness of the raters with regard
to the date of recording were cut out by
an independent technician”, however, no
mention is made about who assessed and
recorded the adverse events (only this data
was used from this study in this review)
Lyketsos 2003
Methods Randomised, placebo-controlled, parallel, 12-week, flexible clinical trial after a 1-week,
single-blind placebo phase
Participants Country: USA
Setting: 44 outpatients
Inclusion criteria: NINCDS-ADRDA for probable Alzheimer’s disease, and DSM-IV
for major depressive episode, MMSE =>10
Exclusion criteria: unstable medical condition, lifetime diagnosis of schizophrenia, bipo-
lar, pre-AD anxiety disorder, current substance misuse, acutely suicidal or requiring hos-
pital admission
Interventions 1. Sertraline (25 mg titrated to 150 mg/day, mean peak doses 113 mg)
2. Placebo
Outcomes The principal outcome measure was response to treatment.
Cornell Scale for Depression in Dementia (CSDD)
Hamilton Depression Rating Scale
Activities of daily living subscale of the Psychogeriatric Dependency Rating Scales
The Neuropsychiatric Inventory (NPI)
MMSE
Notes Good, well-designed study. Attempted to address the diagnostic difficulties, e.g. possible
overlap of symptoms of Alzheimer’s disease and major depression, if DSM-IV criterion 2
were to count toward the diagnosis of depression of major depressive episode it had to be
clearly because of loss of pleasure (anhedonia) and not entirely because of loss of interest.
Similarly, DSM criterion 8 had to be attributed to indecisiveness and not entirely due
to difficulty concentrating
Supported by NIMH, Bethesda, Md. grant 1R01-MH56511. Dr Lyketsos has been or
is a consultant and advisor for and has received or receives research support from several
companies, as declared in the paper
Risk of bias
Bias Authors’ judgement Support for judgement
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Random sequence generation (selection
bias)
Low risk “patients were assigned randomly using
a random numbers generating computer
program, in blocks of 6, without stratifica-
tion, to sertraline or to placebo”
Allocation concealment (selection bias) Low risk The research pharmacist implemented ran-
dom allocation and masked treatment as-
signment was communicated by telephone
to study staff
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk “Identical appearing pills.” Response to
treatment was rated by 2 study psychia-
trists (PVR or MS), who reviewed patients’
scores onbaseline and follow-updepression
rating scales after the study was completed.
Rated each patient on 3-point global scale
as a non-responder, partial responder or full
responder. These psychiatristswere blind to
medication or placebo and did not person-
ally manage any patient in the study. No
algorithm was used, instead they used their
best clinical judgement. If there were any
disagreements, the 2 raters met to provide
a mutually agreeable rating
Incomplete outcome data (attrition bias)
All outcomes
Low risk 50 patients signed consent, 3 did not meet
criteria, therefore 47 entered the wash-in
phase. 3 patients withdrew prior to ran-
domisation (1 hospitalised for depression,
1 due to delirium due to urinary tract in-
fection, and 1 had a cardiac arrest). 24 pa-
tients were randomised to receive sertraline
and 20 placebo. 3 patients withdrew before
completion in the sertraline arm (adverse
events: 1, lack of efficacy: 2) and 5 in the
placebo arm (death: 1, lack of efficacy: 3,
withdrawal of consent: 1). These attrition
figures are acceptable
Selective reporting (reporting bias) Low risk The prespecified outcome measures were
all reported. However, the adverse event
data could not be included in our review,
because they were presented for every 3-
week period and the numbers could not be
combined
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Identical appearing pills.”
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Response to treatment was rated by 2 study
psychiatrists (PVR or MS), who reviewed
patients’ scores on baseline and follow-up
depression rating scales after the study was
completed. Rated each patient on 3-point
global scale as a non-responder, partial re-
sponder or full responder. These psychia-
trists were blind to medication or placebo
and did not personally manage any patient
in the study. No algorithm was used, in-
stead they used their best clinical judge-
ment. If there were any disagreements, the
2 ratersmet to provide amutually agreeable
rating
Petracca 1996
Methods Randomised (“patients were first randomized to receive 6 weeks of clomipramine or
an identical placebo. After a 2 week washout period, they received the complementary
treatment (placebo or clomipramine)”), double-blind, placebo controlled, cross-over
design: 6 weeks + 2 weeks washout + 6 weeks
Participants Country: Argentina
Setting: Neurology outpatient clinic
Recruitment: “consecutive series of patients attending the Neurology Outpatient Clinic
with progressive cognitive decline”
Number: 24 (91% female)
Mean age: 72 (7.3)
Mean MMSE: 21.5
Inclusion criteria: NINCDS-ADRDA for probable dementia, DSM-III-R for dysthymia
or major depression, Hamilton Depression Rating Scale > 10, Hachinski Ischaemic score
< 4
Exclusion criteria: MMSE < 10, psychotropic or cognition enhancing drugs, no carer to
monitor drug adherence
Interventions 1. Clomipramine (titrated from 25 mg to 100 mg/day by 4 weeks)
2. Placebo
Outcomes Ham-D
MMSE
Functional Independence Measure (FIM) score
The following data were received following correspondence with authors
Ham-D
1. Treatment (n = 11)
2. Placebo (n = 10)
3. Ham-D favours active drug
FIM
1. Treatment, mean change +0.27, SD4.08;
41Antidepressants for treating depression in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Petracca 1996 (Continued)
2. Placebo, mean change -0.81, SD11.58
3. ’3-way ANOVA for FIM scores (activities of daily living) revealed no significant
main effects or interactions), P = .273
MMSE
1. Treatment, mean change +0.36, SD7.16
2. Placebo, mean change -0.30, SD12.00
Significant improvement on depression scores, no difference in MMSE scores
Notes Statistical elaboration was received from the authors.
Partially supported from the Raul Carrea Institute of Neurological research, a fellowship
toG.P. fromQualitasMedicina, and a grant fromFundacion Perez Companc, as declared
in the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Consecutive series of patients presenting
with cognitive decline meeting inclusion
and exclusion criteria were “randomized to
either 6 weeks of clomipramine, followed
by a 2-week washout period and 6-weeks
of placebo, or 6 weeks of placebo, followed
by a 2-week washout period and 6 weeks of
clomipramine”. No information was given
on how the randomisation was carried out
Allocation concealment (selection bias) Unclear risk Description of this was not included.
Blinding (performance bias and detection
bias)
All outcomes
Low risk Diagnostic assessments were made by a
psychiatrist blind to the remaining clini-
cal data. “Clomipramine or placebo was
given in a single daily bedtime dose. The
tablets containing 25 mg of clomipramine
or placebo were identical in appearance,
and patients received a fixed number of
tablets (active drug or placebo).” “The pres-
ence of adverse effects was determined by
using a structured questionnaire, and pills
were counted to monitor compliance.” “To
permit assessment of the integrity of the
double blind, the (blind) examiner judged
whether the patient was on active drug or
placebo at the time of the final evaluation
of each treatment arm. Examiners did not
appear to be able correctly to guess alloca-
tion status. ”Serumclomipraminewasmea-
sured [...] and results were not released to
clinicians until the study was over.“
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Incomplete outcome data (attrition bias)
All outcomes
Low risk ”Patients in whom severe side effects (such
as delirium) developed were dropped from
the study and their treatment codes were
broken. Data for these patients were not
included in the statistical analysis. [...]
Twenty-one out of 24 patients (88%) who
were randomised to enter the study com-
pleted the drug trial. One patient who was
on placebo became suicidal and had to be
put on active drug. Another patient, who
was also on placebo, left the study after 4
weeks of treatment. The third patient who
did not complete the study developed an
acute confusional syndrome while he was
on clomipramine (100 mg/day) and had to
be removed from the study.“
Selective reporting (reporting bias) Low risk Results for all outcome measures have been
provided on contacting the authors
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Diagnostic assessments were made by a
psychiatrist blind to the remaining clini-
cal data. ”Clomipramine or placebo was
given in a single daily bedtime dose. The
tablets containing 25 mg of clomipramine
or placebo were identical in appearance,
and patients received a fixed number of
tablets (active drug or placebo).“ ”The
presence of adverse effects was determined
by using a structured questionnaire, and
pills were counted to monitor compliance.
“ ”Serum clomipramine was measured [...
] and results were not released to clinicians
until the study was over.“
Blinding of outcome assessment (detection
bias)
All outcomes
Low risk ”The presence of adverse effects was de-
termined by using a structured question-
naire, and pills were counted to monitor
compliance.“ ”To permit assessment of the
integrity of the double blind, the (blind)
examiner judged whether the patient was
on active drug or placebo at the time of
the final evaluation of each treatment arm.
Examiners did not appear to be able cor-
rectly to guess allocation status. “Serum
clomipramine was measured [...] and re-
sults were not released to clinicians until
the study was over.”
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Methods Placebo controlled, 6 week duration, parallel design
Participants Country: Argentina
Setting: Neurology outpatient clinic
Recruitment: consecutive series of patients attending the Neurology Outpatient Clinic
with progressive cognitive decline
Number: 41
Mean age: 70.8
Mean MMSE: 23.2
Inclusion criteria: NINCDS-ADRDA for probable dementia and DSM-IV for either
minor or major depression, Hamilton Depression Scale greater or equal to 14, Hachinski
Ischaemic score < 4
Exclusion criteria: MMSE < 10, psychotropic or cognition enhancing drugs, no carer to
monitor drug adherence
Interventions 1. Fluoxetine 10 mg for week 1, 20 mg week 2, 30 mg week 3, 40 mg weeks 4 to 6.
2. Placebo - identical in appearance
Outcomes Ham-D
MMSE
FIM score
Notes Patients with minor depression were included.
Partially supported by grants from CONICET, the Legado Peruilh Foundacion, and the
Perez Companc Foundation, as declared in the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk Consecutive series of outpatients attending
a dementia clinicmeeting inclusion and ex-
clusion criteria were randomised to receive
either 6 weeks of fluoxetine or placebo. No
information was given on how the ran-
domisation was carried out
Allocation concealment (selection bias) Unclear risk Description of this was not included.
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Six subjects (four on placebo and two on
fluoxetine) withdrew from the study be-
fore completion, all of themwithin the first
2 weeks of the trial. One of the two sub-
jects on fluoxetine developed a mild confu-
sional state, whereas the remaining subject
declined further participation due to lack
of improvement or interest in the study.
One subject on placebo withdrew from the
study due to gastrointestinal side effects,
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whereas the remaining three subjects de-
cline participation due to lack of improve-
ment or difficulty getting to the center for
repeated evaluations. There were no signif-
icant differences in background variables
between subjects on fluoxetine (n = 15)
or placebo (n = 20) who completed the
drug trial.”The attrition (6/41)was 14.6%,
which is relatively high, however, the num-
ber of completers (n = 35) was sufficient
to provide the prespecified 80% power to
detect between group differences in the
HAM-D scores
Selective reporting (reporting bias) Low risk Results are reported for all outcome mea-
sures.
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “The capsules containing 20 mg of fluox-
etine and those containing placebo were
identical in appearance, and patients re-
ceived a fixed number of capsules (active
drug or placebo).” “The presence of adverse
effects was determined by using a struc-
tured questionnaire. Pills were counted to
monitor compliance.” No further descrip-
tion of how blinding was checked was pro-
vided
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk No description of how blinding was
checked was provided.
Reifler 1989
Methods Placebo controlled: “random assignment trail of imipramine or placebo”, parallel group,
duration: 8 weeks
Participants Country: USA
Setting: “selected from 2 University of Washington outpatient settings”
Recruitment: see above
Number: 61 (59% female), of whom 28 had a depressive illness and dementia.
Mean age: 72 (8)
Inclusion criteria: DSM-III for primary degenerative dementia and major depressive
disorder, MMSE =< 25, 17-item Hamilton RSD => 15
Exclusion criteria: depression too severe for outpatient therapy, psychotropic or cognition
enhancing medication, no family member to ensure medication adherence and keeping
appointments
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Interventions 1. Imipramine average dose of 83 mg/day
2. Placebo
Outcomes Ham-D
MMSE
OARS ADL
Notes Supported by NIMH grant MH-36596. Ciba-Geigy provided the imipramine and
placebo used in the study, as declared in the paper
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk No information provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk The authors state that the imipramine and
placebo tablets were “identical in appear-
ance” and “all parties were blind to the
nature of the medication throughout the
study”, but they do not report any methods
to check on the latter
Incomplete outcome data (attrition bias)
All outcomes
Low risk “Of the 61 subjectswithAlzheimer’s disease
who completed the study, 57 completed the
full 8 weeks and four completed the mini-
mum of 6 weeks required for inclusion in
the data analysis (one each from the de-
pressed imipramine and depressed placebo
groups and two from the nondepressed
imipramine group). Subjects who left the
study before week 6 (N = 8) were con-
sidered dropouts. Three dropouts were de-
pressed subjects receiving imipramine: two
were hospitalized (one for congestive heart
failure and one for esophageal problems)
and one dropped out because of trans-
portation problems. Two depressed sub-
jects receiving placebo dropped out: one
had increasing anxiety and feelings of panic
and the other had a change in his ECG.
Two dropouts were from the nondepressed
imipramine group, one because of dehydra-
tion and one because of flu; the sole non-
depressed dropout receiving placebo lost
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interest and decided not to return.” The
dropout rate is slightly high at 11.6%,
but appears symmetrical between the active
drug and placebo arms
Selective reporting (reporting bias) Unclear risk Results with the prespecified outcomemea-
sures are only reported for completers. The
authors say “There were no significant dif-
ferences in side effects between completed
subjects in the imipramine and placebo
groups. Side effects when present were usu-
ally drowsiness or dizziness”, but no de-
tailed information is provided
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk The authors state that the imipramine and
placebo tablets were “identical in appear-
ance” and “all parties were blind to the
nature of the medication throughout the
study”, but they do not report any methods
to check on this
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nodescription of howblinding of outcome
assessors was checked was provided
Rosenberg 2010
Methods Randomised, double-blind, placebo-controlled, parallel assignment, efficacy and tolera-
bility study
Participants Country: USA
Setting: outpatients, multi-centre (5 memory clinics)
Number: 131 (54.2% female), median age of 79 years.
Inclusion criteria: ability of the participant, caregiver or surrogate to provide written
informed
consent, DSM-IV dementia due to Alzheimer’s disease (MMSE = 10-26), stable treat-
ment for Alzheimer’s disease, meeting criteria for depression in Alzheimer’s disease (dAD:
compared with the DSM-IV major depressive disorder requires three [as opposed to five]
or more symptoms within a 2-week period, one of which must be depressed mood or
anhedonia, with irritability as a possible symptom), ability for the participant’s caregiver
to accompany the participant to study visits and participate in the study
Exclusion criteria: presence of a brain disease that might otherwise explain the presence
of dementia, clinically significant hallucinations or delusions, current treatment of an-
tipsychotics, anticonvulsants, and other antidepressants, benzodiazepines, or other psy-
chotropic medications, need for hospitalisation or residence in a nursing facility
Interventions 1. sertraline (range 25-125 mg per day)
2. placebo
12-week efficacy trial
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Outcomes Primary: Modified Alzheimer’s Disease Cooperative Study Clinical Global Impression
of Change (mADCS-CGIC; modified for clinician to rate mood change only)
Secondary:
1. Cornell Scale for Depression in Dementia (CSDD);
2. remission defined as having a CSDD ≤6 and mADCS-CGIC ≤2.
Notes Depression of Alzheimer’s Disease - 2 (DIADS-2) Study
Intention to treat analysis with the imputation of data (missing data estimation) based
on baseline characteristics and follow-up data
Approximately 40% met criteria for major depressive episode.
Participants were ineligible if they were taking antipsychotics, benzodiazepines, or anti-
convulsants (unless for the treatment of preexisting seizure disorder), which may have
selected out some of the more severely ill patients
Treatment adherence assessed by pill counts from returned medication bottles. Signifi-
cantly more participants took their medications as prescribed in the placebo than in the
sertraline-treated group (90.1% vs 83.1%; P = 0.03)
The study was supported byNIHR grants. National Institute ofMental Health scientific
collaborators participated on the trial’s Steering Committee. Sertraline and matching
placebo were provided by Pfizer, Inc., which did not otherwise participate in the design
or conduct of the trial. Nine authors acknowledged receiving research, consultancy and
other support from pharmaceutical companies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk “Participants were recruited from mem-
ory clinics at five academic centers in the
United States.” “Participants were random-
ized by the study’s Coordinating Center [.
..], in a 1:1 ratio to receive sertraline or
placebo [...].” No further information is
provided about the generation of the ran-
dom sequence
Allocation concealment (selection bias) Unclear risk “Because the five clinical sites have demo-
graphically different patient populations
that could affect the distribution of the
outcomes, the randomization schedule was
stratified by clinical site and it was designed
with blocks of permuted length.”No infor-
mation is provided on how allocation sta-
tus was concealed
Blinding (performance bias and detection
bias)
All outcomes
High risk “Participants began treatment with 50-
mg sertraline or identically appearing
placebo tablets”. However, study clini-
cians guessed treatment assignment cor-
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rectly above chance rate in sertraline but
not in placebo group at week 12. “A symp-
tom checklist was derived from the Food
and Drug Administration approved pre-
scribing information for sertraline (listed
in Table 4). Starting at baseline and at
all follow-up visits, participants and their
caregivers were asked about whether any
of these symptoms, or other self-reported
AEs, occurred [...].”
Incomplete outcome data (attrition bias)
All outcomes
Low risk “The planned sample size of 130 was based
on 80% power, 0.05 significance level, and
20% attrition, to detect a difference be-
tween the two treatment groups in the
distribution of the seven categories of the
mADCS-CGIC. [...] Seven participants
(5%) were lost to follow-up during the
first 12 weeks of the study (three sertra-
line treated and four placebo treated). An
additional two participants in the sertra-
line group and three participants in the
placebo group missed their Week 12 study
visit. The proportion of patients discon-
tinuing study medications before Week 12
did not differ significantly between treat-
ment groups (Fisher’s exact test, P 0.64); 12
(18%) participants in the sertraline-treated
group and 9 (14%) in the placebo-treated
group discontinued study medications be-
fore Week 12.” Although the attrition was
relatively high, it was symmetrically so be-
tween the two groups
Selective reporting (reporting bias) Unclear risk The authors reported results with all pre-
specified outcome measures. Nevertheless,
they only presented an intention-to-treat
analysis with imputation of missing data.
This would represent a degree of risk of bias
Blinding of participants and personnel
(performance bias)
All outcomes
High risk “Participants began treatment with 50-mg
sertraline or identically appearing placebo
tablets”. Clinicians had the option of in-
creasing or decreasing the dose after ran-
domisation depending on response and tol-
erability. The study physician guessed treat-
ment assignment correctly above chance
rate in the sertraline but not in placebo
group at week 12. “A symptom checklist
49Antidepressants for treating depression in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Rosenberg 2010 (Continued)
was derived from the Food and Drug Ad-
ministration approved prescribing infor-
mation for sertraline (listed in Table 4).
Starting at baseline and at all follow-up vis-
its, participants and their caregivers were
asked about whether any of these symp-
toms, or other self-reported AEs, occurred
[...].”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Clinicians assessed mood at each visit. The
study physician guessed treatment assign-
ment correctly above chance rate in the ser-
traline but not in placebo group
Roth 1996
Methods Randomised, placebo-controlled, parallel group study design of 6-week duration
Participants Country: international multicentre (41 centres)
Setting: in- and outpatients
Number: 694 (532 females, 162 males)
Age: 60 to 90 years, mean: 73.6 (8.4)
Inclusion criteria:
1. DSM-III for dementia and with depression, or DSM-III for major depressive
episode with cognitive decline;
2. 11< MMSE < 28;
3. 18-item SCAG >= 40;
4. Geriatric Depression Scale >= 5;
5. 17-item Hamilton >= 14.
Exclusion criteria: severe uncontrolled systemic disease, other neurological or major
psychiatric disorder, psychotropic drugs
Interventions 1. Moclobemide 400 mg/day
2. Placebo
Outcomes 1. HAM-D
2. MMSE
3. SCAG
4. CGAE
5. BGP
Notes No specific information on subgroup of patients with DSM depression and DSM de-
mentia (n = 476)
No usable statistics for efficacy analyses; after a discussion by the review team, only the
adverse events data were used
Source of funding not specificallymentioned but likely to have beenHoffmann-LaRoche
Ltd., Basel, Switzerland, manufacturers of moclobemide, as one author was an employee
of the company
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Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk ”random assignment within centre“ - No
further information on randomisation is
provided
Allocation concealment (selection bias) Unclear risk No information provided
Blinding (performance bias and detection
bias)
All outcomes
Unclear risk ”Treatment was with either a fixed dose
of moclobemide 400 mg or a matched
placebo [...]. a placebo run-in period of 14
dayswas envisaged but not rigidly enforced.
Patients with signs of rapid deterioration
during the run-in period were entered into
the double-blind treatment phase, after a
minimum wash-out of four days.“
Incomplete outcome data (attrition bias)
All outcomes
Low risk Out of 726 recruited patients, 14 had un-
classifiable diagnoses and 18 missing effi-
cacy data (but were still included in the ”sa-
fety population“)
Selective reporting (reporting bias) High risk The depression rating scale scores were re-
ported incompletely, therefore, only the ad-
verse event and tolerability data from this
study were used for the purposes of this re-
view. ”The safety data are based on the to-
tal group of randomised patients. All those
who completed 10 days of treatment or
gave as a reason for withdrawal, lack of ef-
ficacy, poor tolerability or adverse effects,
were included in the analysis of efficacy as
the ’intent to treat group’ (ITT). The few
patients who dropped out for any other rea-
son were excluded from the efficacy analy-
sis but were included in the safety analysis
(N = 726)
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Treatment was with either a fixed dose
of moclobemide 400 mg or a matched
placebo [...]. a placebo run-in period of 14
dayswas envisaged but not rigidly enforced.
Patients with signs of rapid deterioration
during the run-in period were entered into
the double-blind treatment phase, after a
minimum wash-out of four days.”
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Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Nodescription of howblinding of outcome
assessors was checked was provided
Weintraub 2010
Methods Randomised, double-blind, placebo-controlled, parallel assignment, safety and efficacy
study, the double-blinded continuation of a 12-week efficacy studywith participants who
showed improvement on the modified Alzheimer’s Disease Cooperative Study Clinical
Global Impression of Change (mADCS-CGIC; modified for clinician to rate mood
change only) after 12 weeks
Participants Country: USA
Setting: outpatients, multi-centre (5 memory clinics)
Number: 131
Inclusion criteria: ability of the participant, caregiver, or surrogate to provide written
informed
consent, DSM-IV dementia due to Alzheimer’s disease (MMSE = 10-26), stable treat-
ment for Alzheimer’s disease, meeting criteria for depression in Alzheimer’s disease (dAD:
different fromDSM-IV major depressive disorder in requiring three [as opposed to five]
or more total symptoms and not requiring the gateway symptoms [most of the day,
nearly every day], distinguishing social isolation or withdrawal from anhedonia, and
adding irritability as a symptom), ability for the participant’s caregiver to accompany the
participant to study visits and participate in the study
Exclusion criteria: presence of a brain disease that might otherwise explain the presence
of dementia, clinically significant hallucinations or delusions, current treatment with
antipsychotics, anticonvulsants, and other antidepressants, benzodiazepines, or other
psychotropic medications, need for hospitalisation or residence in a nursing facility
Interventions 1. Sertraline (range 25-125 mg per day)
2. Placebo
For 24 weeks (12-week efficacy trial + 12-week extension phase with randomised treat-
ment for at least partial responders and the option for open label treatment for non-
responders)
Outcomes Primary:
1. response to treatment;
2. remission from depression.
Measured at 24 weeks measured by the Cornell Scale for Depression in Dementia and
a global response measure (mADCS-CGIC measuring mood, activity enjoyment, neu-
rovegetative [autonomic, i.e. not under conscious control] function and depressive cog-
nitions)
Secondary:
1. non-mood neuropsychiatric symptoms;
2. global cognitive functioning;
3. quality of life.
Measured at Week 24 (in the trial description at clinicaltrials.gov telephone follow-up
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Weintraub 2010 (Continued)
at weeks 36 and 48 is also mentioned)
Notes Reporting on week-24 outcomes of the Depression of Alzheimer’s Disease - 2 (DIADS-
2) Study (12-week extension phase for patients having improved at least minimally)
Intention to treat analysis with the imputation of data (missing data estimation) based
on baseline characteristics and follow-up data
Approximately 40% met criteria for major depressive episode.
The study was supported byNIHR grants. National Institute ofMental Health scientific
collaborators participated on the trial’s Steering Committee. Sertraline and matching
placebo were provided by Pfizer, Inc., which did not otherwise participate in the design
or conduct of the trial. Nine authors acknowledged receiving research, consultancy and
other support from pharmaceutical companies
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Unclear risk As per Rosenberg 2010, “Participants were
recruited from memory clinics at five aca-
demic centers in the United States.” “Par-
ticipants were randomized by the study’s
Coordinating Center [...], in a 1:1 ratio to
receive sertraline or placebo [...].” No fur-
ther information is provided about the gen-
eration of the random sequence
Allocation concealment (selection bias) Unclear risk “Because the five clinical sites have demo-
graphically different patient populations
that could affect the distribution of the
outcomes, the randomization schedule was
stratified by clinical site and it was designed
with blocks of permuted length.”No infor-
mation is provided on how allocation sta-
tus was concealed
Blinding (performance bias and detection
bias)
All outcomes
High risk “Participants began treatment with 50
mg sertraline or identically appearing
placebo tablets” However, study clinicians
guessed treatment assignment correctly
above chance rate in sertraline but not in
placebo group at week 12. “A symptom
checklist was derived from the Food and
Drug Administration approved prescrib-
ing information for sertraline. Starting at
baseline and at all follow-up visits, partici-
pants and their caregivers were asked about
whether any of these symptoms, or other
self-reported AEs, occurred [...].”
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Weintraub 2010 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
High risk The data presented in the consort chart
does not completely tally with that in the
abstract regarding numbers of participants
completing treatment. As per the abstract,
74 participants (56.5%) completed all 24
weeks on randomized treatment; this in-
dicates very significant attrition, which is
made better only partially by the fact that
117 participants (89.3%) completed all
study assessments. All analyses presented
were intention to treat. The authors state
that “Missing outcomes were imputed us-
ing the method of multiple imputation.
Prediction models of the missing data were
estimated based on the patients’ other base-
line and follow-up data...”, but no clear de-
scription is given of how this was done
Selective reporting (reporting bias) Unclear risk The authors reported results with all pre-
specified outcomemeasures.However, they
only presented an intention-to-treat analy-
sis with imputation of missing data
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk “Participants began treatment with 50-mg
sertraline or identically appearing placebo
tablets”. Clinicians had the option of in-
creasing or decreasing the dose after ran-
domisation depending on response and tol-
erability. The study physician guessed treat-
ment assignment correctly above chance
rate in the sertraline but not in placebo
group at week 12. “A symptom checklist
was derived from the Food and Drug Ad-
ministration approved prescribing infor-
mation for sertraline (listed in Table 4).
Starting at baseline and at all follow-up vis-
its, participants and their caregivers were
asked about whether any of these symp-
toms, or other self-reported AEs, occurred
[...].”
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Clinicians assessed mood at each visit. The
study physician guessed treatment assign-
ment correctly above chance rate in the ser-
traline but not in placebo group
ADCS-CGIC: Alzheimer’s Disease Cooperative Study Clinical Global Impression of Change
BGP: Rating Scale for Geriatric Patients
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CGAE: Clinical Global Assessment of Efficacy
CGI: Clinical Global Impression Scale
CSDD: Cornell Scale for Depression in Dementia
FIM score: Functional independence score
GBS: Geriatric-Brane-Steen geriatric rating scale, to assess level of dementia
GDS: Geriatric Depression Scale
Ham-D: Hamilton depression scale
MADRS: Montgomery-Asberg Depression Rating Scale
MMSE: Mini-mental state examination
OARS ADL: Activities of daily living scales
SCAG: Sandoz clinical assessment geriatric scale
UKUSRS UKU: Side Effect Rating Scale
mADCS-CGIC: modified Alzheimer’s Disease Cooperative Study - Clinical Global Impression of Change
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Barak 1996 Excluded as study investigates the properties of inositol which is not generally regarded as an antidepressant
(it is an isomer of glucose and precursor for the second messenger system involving phospatidylinositol, and it
has been reported as having antidepressant properties). This study investigated its utility in improving cognitive
functioning in a group of subjects with Alzheimer’s disease. Subjects whose estimate of depressive symptoms
was higher than minimal were excluded
Brodaty 2003 Patients were diagnosed with dementia, but only some suffered from depression which was not diagnosed using
DSM criteria
Bui 2012 Case report, not a treatment trial
Burke 1994 Case reports of four patients with Alzheimer’s disease and accompanying depression and psychosis treated with
SSRIs
Capote 1978 RCT of patients with senile dementia, but treatment given was not an antidepressant (Cyclandelate is a vasodila-
tor)
Choe 2014 Patients were not depressed
Devanand 2003 No well-defined dementia diagnosis
Drye 2012 Only patients without major depression were included.
Dunbar 2011 Patients were not diagnosed with dementia and depression.
Fairweather 1993 Study (RCT) designed to compare the effects on cognition of fluoxetine and amitriptyline in depressed elderly
patients; patients not demented and study not placebo-controlled
Finkel 2004 Placebo controlled RCT of sertraline, patients diagnosed with probable AD, all on donepezil, and with be-
havioural manifestations but not necessarily depressed
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Flicker 1998 Presentation of published work (clarified by correspondence with authors)
Gottfries 1991 Subjects do not meet criteria for depression, it is a study of citalopram for ’emotional disturbance’ associated
with dementia
Gottfries 1992 Review article reviewing the 2 Nyth studies
Hoyberg 1996 RCT of mirtazapine in the depressed elderly, but they were not demented
Jenike 1985 Case reports of two patients with Alzheimer’s disease and depression who failed to respond to standard antide-
pressants but did respond to MAOIs
Karlsson 2000 RCT of citalopram vs mianserin in depressed elderly patients who may also have had dementia, but not placebo
controlled, therefore excluded
Katona 1998 Not placebo controlled, imipramine compared with paroxetine in cognitively impaired, depressed patients
Lebert 2006 No standardised criteria for the diagnoses of dementia and depression
Magai 2000 Although the participants were demented, only 10% were also diagnosed cases of major depression
Mizukami 2009 No placebo group
Mokhber 2014 No placebo group
Moretti 2003 Study of paroxetine vs piracetam for patients with frontotemporal dementia, and behavioural manifestations,
but not depression
Mossello 2008 Retrospective study, no blinding to treatment status, no formal criteria used to define depression
Mowla 2007 The patients were not diagnosed with depression.
Nebes 2003 Study of citalopram vs placebo for patients with probable AD, all on donepezil, all with behavioural symptoms
which may include depression; not clear whether it is randomised
Nelson 2006 No clear dementia diagnosis, no placebo control
Nyth 1990 Combined double-blind and open technique; looks at the effect of citalopram on emotional disturbance in pa-
tients with various subtypes of dementia; patients are not diagnosed with depression according to any recognised
criteria
Nyth 1992 Amalgamated depressed patients also suffering from somatic disorders or dementia (or both); out of the 149
patients, 98 had DSM-III major depression and 29 dementia; those with concurrent dementia and depression
not separated
Oslin 2000 Two trials, one open-label of sertraline, another an RCT of low versus high dose nortriptyline, but no placebo
group; patients were depressed and some may have been demented
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Oslin 2003 RCT of venlataxine versus sertraline in patients with DSM-IV diagnosed depressive disorder and dementia; no
placebo group
Passeri 1987 Participants did not meet recognised criteria for depressive illness; minaprine not generally available or used as
an antidepressant
Pelton 2008 Study on donepezil augmentation to antidepressant treatment, no blinding to antidepressant treatment status
Pelton 2014 Not an antidepressant RCT
Peters 2011 Not a treatment trial
Pollock 2007 Study on treatment of behavioural and psychotic symptoms with risperidone or citalopram in dementia; non-
depressed patients
Reynolds III 1987 Open trial, not randomised, placebo-controlled or double-blind
Rozzini 2010 Not an RCT, not blind
Smith 1984 N = 28, severely demented, six with endogenous or reactive depression; no information on whether formal
diagnostic criteria met. In addition to the above problems, they used a cross-over design, all patients prescribed
tryptophan for one month, and then switched to placebo
Streim 2000 There was no placebo group. The study examined response to high and low dose nortriptyline among 69
patients living in nursing homes. Patients were depressed according to psychiatric interview and depression
scales. Moderate cognitive impairment was not a reason for exclusion
Swartz 1997 Not randomised, double-blind or placebo-controlled; not specifically looking at dementia
Taragano 1997 Randomised trial of amitriptyline vs fluoxetine, for patients with probable AD and major depressive disorder,
but not placebo-controlled
Teranishi 2013 BPSD, not depression per se; no placebo group
van Asch 2013 Not an RCT
AD: Alzheimer’s disease
BPSD: behavioural and psychological symptoms of dementia
MAOIs: monoamine oxidase inhibitors
RCT: randomised controlled trial
SSRIs: selective serotonin reuptake inhibitors
VD: vascular dementia
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Characteristics of studies awaiting assessment [ordered by study ID]
Sverdlik 2005
Methods Randomised, double-blind, placebo-controlled, parallel assignment, interventional efficacy study
Participants Age 60 years and above, diagnosed with AD, VD, or mixed AD and VD and major depressive episode according to
DSM-IV
Interventions Escitalopram or placebo treatment for 8 weeks
Outcomes Primary: Cornell Scale foe Depression in Dementia (CSDD) total score
Secondary: Cohen-Mansfield Agitation Inventory (CMAI)
Notes Anticipated end date: not known
(As per ClinicalTrials.gov on 11 March 2015, “status unknown”.)
We emailed Dr Anna Sverdlik on 14 Jan 2014, but have not received any response as of 15 July 2015
AD: Alzheimer’s disease
SSRIs: selective serotonin reuptake inhibitors
VD: vascular dementia
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D A T A A N D A N A L Y S E S
Comparison 1. Antidepressant versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Depression endpoint mean
scores at 6-13 weeks
8 614 Std. Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.26, 0.06]
1.1 SSRIs 5 400 Std. Mean Difference (IV, Fixed, 95% CI) -0.13 [-0.33, 0.07]
1.2 Mirtazapine 1 134 Std. Mean Difference (IV, Fixed, 95% CI) -0.02 [-0.37, 0.33]
1.3 Venlafaxine 1 31 Std. Mean Difference (IV, Fixed, 95% CI) -0.09 [-0.80, 0.62]
1.4 TCA 2 49 Std. Mean Difference (IV, Fixed, 95% CI) -0.10 [-0.67, 0.46]
2 Cornell Scale for Depression in
Dementia (CSDD)
4 Mean Difference (Random, 95% CI) Subtotals only
2.1 At week 6-13 3 433 Mean Difference (Random, 95% CI) -0.10 [-0.99, 0.78]
2.2 At 6-9 months 2 357 Mean Difference (Random, 95% CI) 0.59 [-1.12, 2.30]
3 Hamilton Depression rating
Scale (HDRS)
4 134 Mean Difference (IV, Fixed, 95% CI) -0.85 [-2.65, 0.95]
4 Number of responders (ITT) at
6-12 weeks
3 116 Odds Ratio (M-H, Fixed, 95% CI) 1.71 [0.80, 3.67]
4.1 SSRI 2 85 Odds Ratio (M-H, Fixed, 95% CI) 2.42 [0.97, 6.09]
4.2 venlafaxine 1 31 Odds Ratio (M-H, Fixed, 95% CI) 0.73 [0.17, 3.11]
5 Number of responders (ITT) at
24 weeks
1 131 Odds Ratio (M-H, Fixed, 95% CI) 1.45 [0.72, 2.92]
6 Number of patients with
remission (ITT) at 6-12 weeks
4 240 Odds Ratio (M-H, Fixed, 95% CI) 2.57 [1.44, 4.59]
6.1 SSRI 3 216 Odds Ratio (M-H, Fixed, 95% CI) 2.22 [1.20, 4.12]
6.2 TCA 1 24 Odds Ratio (M-H, Fixed, 95% CI) 9.0 [1.42, 57.12]
7 Number of patients with
remission (ITT) at 24 weeks
1 131 Odds Ratio (M-H, Fixed, 95% CI) 1.75 [0.80, 3.82]
8 Cognitive function endpoint
mean scores
6 Mean Difference (IV, Fixed, 95% CI) Subtotals only
8.1 Mini-mental state scores
at 6-12 weeks
5 194 Mean Difference (IV, Fixed, 95% CI) 0.33 [-1.31, 1.96]
8.2 Mini-mental state scores
at 6-9 months
1 131 Mean Difference (IV, Fixed, 95% CI) 1.0 [-1.14, 3.14]
9 Change in MMSE mean scores 6 Mean Difference (Fixed, 95% CI) Subtotals only
9.1 at 6 to13 weeks 5 Mean Difference (Fixed, 95% CI) 0.19 [-0.81, 1.19]
9.2 at 6-9 months 2 Mean Difference (Fixed, 95% CI) -0.38 [-1.90, 1.13]
10 Activities of daily living,
endpoint values at 6-13 weeks
4 173 Std. Mean Difference (IV, Fixed, 95% CI) -0.05 [-0.36, 0.25]
11 Activities of daily living at 6-9
months
1 Mean Difference (IV, Fixed, 95% CI) Totals not selected
12 Tolerability: Number of
dropouts at 6-13 weeks
9 836 Odds Ratio (M-H, Fixed, 95% CI) 1.51 [1.07, 2.14]
12.1 SSRI 5 462 Odds Ratio (M-H, Fixed, 95% CI) 1.39 [0.88, 2.21]
12.2 venlafaxine 1 31 Odds Ratio (M-H, Fixed, 95% CI) 3.5 [0.68, 17.96]
12.3 mirtazapine 1 164 Odds Ratio (M-H, Fixed, 95% CI) 1.79 [0.71, 4.49]
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12.4 older antidepressants 3 179 Odds Ratio (M-H, Fixed, 95% CI) 1.39 [0.69, 2.80]
13 Tolerability: Number of
dropouts at 6-9 months
2 457 Odds Ratio (M-H, Fixed, 95% CI) 1.25 [0.83, 1.88]
14 Safety: number experiencing at
least one adverse event
3 1073 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.55 [1.21, 1.98]
14.1 Older antidepressants 2 747 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.41 [1.06, 1.89]
14.2 Mirtazapine 1 164 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.83 [0.93, 3.57]
14.3 SSRI 1 162 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.11 [1.08, 4.13]
15 Safety: N experiencing at least
one event of dry mouth
5 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.80 [1.23, 2.63]
15.1 Older antidepressants 3 874 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.71 [1.09, 2.68]
15.2 SSRI 2 170 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.04 [1.01, 4.12]
16 Safety: N experiencing at least
one event of fatigue
3 982 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.22 [0.79, 1.87]
16.1 Older antidepressants 2 853 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.28 [0.78, 2.10]
16.2 SSRI 1 129 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.06 [0.45, 2.50]
17 Safety: N experiencing at least
one event of constipation
5 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.18 [0.76, 1.83]
17.1 Older antidepressants 3 874 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.18 [0.68, 2.06]
17.2 SSRI 2 170 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.17 [0.56, 2.43]
18 Safety: N experiencing at least
one event of dizziness
5 1044 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.00 [1.34, 2.98]
18.1 Older antidepressants 3 874 Peto Odds Ratio (Peto, Fixed, 95% CI) 1.64 [1.00, 2.68]
18.2 SSRI 2 170 Peto Odds Ratio (Peto, Fixed, 95% CI) 2.93 [1.48, 5.80]
A D D I T I O N A L T A B L E S
Table 1. Outcome measures
Outcome measure Abbreviation Reference Type of measure Brief description Used in
Depression rating scales
Hamilton Depres-
sion Rating Scale
HAMD Hamilton 1960 depressive symptom
levels
Clinician-rated, mul-
tiple choice rat-
ing scale of depressive
symptom severity de-
signed to be sensitive
to change with treat-
ment in the general
adult population
Reifler 1989, Petracca
1996, Petracca 2001,
Lyketsos 2003
Cornell Scale for
Depression in De-
mentia
CSDD Alexopoulos 1988 depressive symptom
levels
For the diagnosis of
depression in patients
with a dementia syn-
drome administered
by a clinician. It takes
20 minutes with the
carer and 10 minutes
Lyketsos 2003,
Weintraub 2010
Banerjee 2011,
60Antidepressants for treating depression in dementia (Review)
Copyright © 2018 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Table 1. Outcome measures (Continued)
with the patient. The
scale has 19 items,
rated on a 3 point
scale: absent, mild or
intermittent and se-
vere, based on the
week prior to the in-
terview
Montgomery
Asberg Depression
Rating Scale
MADRS Montgomery 1979 depressive symptom
levels
A 10-item clinician-
rated diagnostic ques-
tionnaire to measure
the severity of depres-
sive symptomatology
in mood disorders
de Vasconcelos 2007
Geriatric
Depression Scale
GDS Yesavage 1982 depressive symptom
levels
A 30-item, self-report
as-
sessment used to iden-
tify depression in the
elderly. The simple re-
sponse format (yes/
no questions)makes it
more suitable for use
in those with cogni-
tive impairment
Fuchs 1993
Cognitive measure
Mini-mental State
Examination
MMSE Folstein 1975 level of cognitive
functioning
A 30-point clinician-
administered cogni-
tive test for cognitive
impairment, assessing
orientation, concen-
tration, memory, lan-
guage, and visuo-spa-
tial function. Higher
scores indicate better
functioning
All included studies
Activities of daily living
Psy-
chogeriatric depen-
dency rating scales -
ADL subscale
PGDRS-ADL Wilkinson 1980 need for assistance
with functional abili-
ties
Physical capacity con-
sists of 7 sub-cate-
gories. Higher scores
indicate more disabil-
ity
Lyketsos 2003
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Table 1. Outcome measures (Continued)
Alzheimer’s Disease
Cooperative Study -
Activities of Daily
Living Scale
ADCS-ADL Galasko 1997 functional ability Informant-based, last
4 weeks. Higher score
indicates better per-
formance
Weintraub 2010
Functional Inde-
pendence Measure
FIM Granger 1986 need for assistance
with functional abili-
ties
18 items on self-
care, sphincter con-
trol, mobility, loco-
motion, communica-
tion, social cognition.
Higher scores indicate
more disability
Petracca 1996,
Petracca 2001
Older American Re-
sources and Services
OARS-ADL Pfeiffer 1975 functional ability An 14-item
assessment for physi-
cal function, includ-
ing bathing, dressing,
grooming, and conti-
nence, relying on self
report. Higher scores
indicate better func-
tioning
Reifler 1989
Seoul-Instru-
mental Activities of
Daily Living
SIADL Ku 2004 instrumental
everyday activities
A 15-item instrument
to
assess complex func-
tions of daily living,
with a total score from
0 to 45. Higher scores
reflect worse function
An 2017
Table 2. Baseline characteristics and diagnostic criteria - included studies
Trial dementia
criteria
depression
criteria
number of
patients
duration interven-
tion
mean age mean
MMSE
mean de-
pression rat-
ing scale
score
An 2017 NINCDS-
ADRDA for
AD
three or
more from
Olin’s crite-
ria for de-
pression in
AD
84 8 weeks 5 mg/day of
escitalo-
pram,
increased 5
mg/day ev-
ery two
weeks, up to
a maximum
dosage of 15
mg/day
75.2 (6.9) 18.85 CSDD: 11.
39
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Table 2. Baseline characteristics and diagnostic criteria - included studies (Continued)
Banerjee
2011
NINCDS-
ADRDA for
probable or
possible AD
depression
≥ 4 weeks’s
duration po-
ten-
tially need-
ing antide-
pressants;
CSDD ≥ 8
326 39 weeks sertraline 70
mg/d (target
dose: 150
mg/d), mir-
tazapine 24
mg/d (target
dose: 45mg/
d)
79.3 18.1 CSDD: 12.9
de
Vasconcelos
2007
DSM-IV for
dementia
(AD, VD,
and mixed)
DSM-
IVmajor de-
pressive
disorder and
CSDD
31 6 weeks ven-
lafaxine (37.
5-131.25
mg/d, mean
= 75 mg/d)
77.6 (6.4) (range: 10-
24)
MADRS:
24.5 (7.1)
Fuchs 1993 DSM-III-R
for PDD
DSM-III-R
290.21
(mildly de-
pressed)
127 8 weeks mapro-
tiline (25mg
titrated
to 75 mg/d,
mean max.
dose 59 mg/
d)
80 (48-96) 15.4 (0-30) GDS
(median): 8
Lyketsos
2003
NINCDS-
ADRDA for
probable
AD
DSM-VI for
major
depressive
episode
44 12 weeks sertra-
line (25 mg
titrated to
150
mg/d, mean
peak dose
113 mg)
77.7 16.9 Ham-D: 22.
75
Petracca
1996
NINCDS-
ADRDA for
probable
AD
DSM-III-
R for dys-
thymia
or major de-
pression
24 6 weeks + 6
weeks clomipramine
(25 mg
titrated to
100 mg/d)
72 (7.2) 21.5 (6.2) Ham-D:17.
5 (6.0)
Petracca
2001
NINCDS-
ADRDA for
probable
AD
DSM-IV
criteria for
either major
or minor de-
pression
41 6 weeks flu-
oxetine (10
mg titrated
to 40 mg/d)
70.8 23.2 Ham-D: 16.
5
Reifler 1989 DSM-III for
PDD
DSM-III
(major de-
pressive dis-
order)
28 8 weeks imipramine
(mean dose
83 mg/d)
72 (8) 17.5 (5.1) Ham-D: 18.
9 (3.8)
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Table 2. Baseline characteristics and diagnostic criteria - included studies (Continued)
Rosenberg
2010
DSM-IV for
AD
Criteria for
depression
of AD
131 12 weeks sertraline 50
mg/
d increased
to 100 mg/
d, mean =
93.1 mg/d)
77.3 (8.0) 20.0 (4.6) CSDD (me-
dian)
: 13 (1st and
3rd quartile:
9, 18)
Roth 1996 DSM-III for
dementia
DSM-III for
major
depressive
episode
726 6 weeks moclobe-
mide (400
mg/d)
74.4 (8.5) 20.2 (4.8) 24.5 (5.3)
Weintraub
2010
(ex-
tension of
Rosenberg
2010)
DSM-IV for
AD
Criteria for
depression
of AD
131 24 weeks randomised
treatment
with sertra-
line for at
least partial
re-
sponders af-
ter week 12
77.3 (8.0) 20.0 (4.6) CSDD (me-
dian)
: 13 (1st and
3rd quartile:
9, 18)
WH A T ’ S N E W
Last assessed as up-to-date: 16 August 2017.
Date Event Description
16 August 2017 New citation required and conclusions have changed New studies included. Background and methods were up-
dated in line with MECIR standards, and GRADE incor-
porated. Conclusions changed
16 August 2017 New search has been performed The most recent search for this review was performed on
16 August 2017
H I S T O R Y
Protocol first published: Issue 2, 1998
Review first published: Issue 4, 2002
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Date Event Description
22 July 2016 New search has been performed A top-up search was performed for this review on 22
July 2016.Nonew studies were identified for inclusion
from this search
12 November 2014 New search has been performed A new literature search has been carried out.
1 December 2013 New search has been performed A pre-publication searchwas performed for this review
on 1 December 2013
17 May 2012 New search has been performed A new search was performed for this review in May
2012. The new search retrieved new studies for con-
sideration by the authors
29 November 2010 Amended A new search was performed for this review on 29
November 2010. The search retrieved new studies for
consideration by the authors
21 May 2009 New search has been performed Update searches of December 2007 andOctober 2008
retrieved new studies for consideration by the authors
52 references were retrieved in a new search.We found
only one trial that met our inclusion criteria for this
review (de Vasconcelos 2007). There were three on-
going studies registered on Clinicaltrials.com Baner-
jee 2006, Lyketsos 2004a, Sverdlik 2005a. There is no
clear evidence that antidepressants are effective in the
treatment of depression in dementia
21 May 2008 Amended Converted to new review format.
24 August 2005 New search has been performed Update 2005: new searches in the 2005 edition of the
British National Formulary (BNF) used the follow-
ing extra search terms: escitalopram or cipralex or do-
sulepin or dothapex or prepadine
17 July 2002 New citation required and conclusions have changed Substantive amendment
C O N T R I B U T I O N S O F A U T H O R S
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